Compound

L-cysteine

A thiol-containing non-essential amino acid that is oxidized to form cystine.

Definition from MeSH (D003545), National Library of Medicine, read 2026-09-23. NLM revises MeSH; this copy may not reflect its current record.

CHEBI:17561ChEBI

Open in the graph

Studied for

6 endpoints · 6 findings · 2 papers · 4 null

Intraventricular haemorrhage incidenceno detected effectEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
Necrotising enterocolitis incidenceno detected effectEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
Reduced glutathione concentrationno detected effectEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
Retinopathy of prematurity incidenceno detected effectEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
Body masslowersEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.

All 6 endpoints, with the quotes

Structure

2D depiction · 3D model shown

Loading the model…

A generated conformer of L-cysteine — one low-energy arrangement PubChem computed, not a measured structure. Hydrogens are not drawn; the formula counts them.

Class: Organic compound
Formula: C3H7NO2S
Mass: 121.161 g/mol
Charge: 0
InChIKey: XUJNEKJLAYXESH-REOHCLBHSA-N
SMILES: N[C@@H](CS)C(=O)O
Look it up: ChEBI PubChem By InChIKey

Identity from ChEBI, geometry from PubChem. Not evidence.

What the evidence says

How to read these marks

6 findings · 6 endpoints · 2 papers · 4 null · by evidence strength

Heavier lines are better evidence, and a line with a gap in the middle is an inference rather than a reported result. Two lines arriving at one endpoint are two findings of it, marked ×2. How evidence strength is computed.

What moved

2 findings

Decreases body mass
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“To test this hypothesis, we gavaged mice with cysteine and observed a decrease in body weight and fat storage.”
Quoted verbatim from Dietary cysteine drives body fat loss via FMRFamide signaling in Drosophila and mouse..
Study

animal · not in humans
Participants

10
Duration

2 months
Dose

cysteine 4 mmol/kg per day, oral gavage, 60 days
Population

C57BL/6J male mice, orally gavaged with cysteine vs water
Dietary cysteine drives body fat loss via FMRFamide signaling in Drosophila and mouse.2023PMID:37055592Permalink
Decreases fat mass
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“To test this hypothesis, we gavaged mice with cysteine and observed a decrease in body weight and fat storage.”
Quoted verbatim from Dietary cysteine drives body fat loss via FMRFamide signaling in Drosophila and mouse..
Study

animal · not in humans
Participants

10
Duration

2 months
Dose

cysteine 4 mmol/kg per day, oral gavage, 60 days
Population

C57BL/6J male mice, orally gavaged with cysteine vs water
Dietary cysteine drives body fat loss via FMRFamide signaling in Drosophila and mouse.2023PMID:37055592Permalink

What did not

4 findings

No detected effect on reduced glutathione concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“The CYS and ISO group means were not different for total glutathione, GSH, and GSH:GSSG, neither at enrollment nor infusion day (Table 2).”
Quoted verbatim from Effect of High-Dose Cysteine Supplementation on Erythrocyte Glutathione: A Double-Blinded, Randomized Placebo-Controlled Pilot Study in Critically Ill Neonates..
Study

RCT
Dose

cysteine-HCl 121 mg/kg/day in parenteral nutrition with sodium acetate 2 mEq/kg/day
Population

Critically ill neonates on mechanical ventilation and parenteral nutrition (SNAP > 10); intracellular erythrocyte GSH at enrollment and on infusion day, about study day 7; comparator is isonitrogenous additional parenteral amino acids without cysteine
Effect of High-Dose Cysteine Supplementation on Erythrocyte Glutathione: A Double-Blinded, Randomized Placebo-Controlled Pilot Study in Critically Ill Neonates.2016PMID:25139979Permalink
No detected effect on necrotising enterocolitis incidence
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“No difference was found in the CYS and ISO groups with regards to the percent of subjects diagnosed with necrotizing enterocolitis (29% vs. 24%, p=1), intraventricular hemorrhage grade III and IV (19% vs. 24%, p=1), and need for laser treatment for retinopathy of prematurity (24% vs. 24%, p=1).”
Quoted verbatim from Effect of High-Dose Cysteine Supplementation on Erythrocyte Glutathione: A Double-Blinded, Randomized Placebo-Controlled Pilot Study in Critically Ill Neonates..
Study

RCT
Dose

cysteine-HCl 121 mg/kg/day in parenteral nutrition with sodium acetate 2 mEq/kg/day
Population

Critically ill neonates on mechanical ventilation and parenteral nutrition (SNAP > 10); comparator is isonitrogenous additional parenteral amino acids without cysteine
Effect of High-Dose Cysteine Supplementation on Erythrocyte Glutathione: A Double-Blinded, Randomized Placebo-Controlled Pilot Study in Critically Ill Neonates.2016PMID:25139979Permalink
No detected effect on intraventricular haemorrhage incidence
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“No difference was found in the CYS and ISO groups with regards to the percent of subjects diagnosed with necrotizing enterocolitis (29% vs. 24%, p=1), intraventricular hemorrhage grade III and IV (19% vs. 24%, p=1), and need for laser treatment for retinopathy of prematurity (24% vs. 24%, p=1).”
Quoted verbatim from Effect of High-Dose Cysteine Supplementation on Erythrocyte Glutathione: A Double-Blinded, Randomized Placebo-Controlled Pilot Study in Critically Ill Neonates..
Study

RCT
Dose

cysteine-HCl 121 mg/kg/day in parenteral nutrition with sodium acetate 2 mEq/kg/day
Population

Critically ill neonates on mechanical ventilation and parenteral nutrition (SNAP > 10); severe grades III and IV only; comparator is isonitrogenous additional parenteral amino acids without cysteine
Effect of High-Dose Cysteine Supplementation on Erythrocyte Glutathione: A Double-Blinded, Randomized Placebo-Controlled Pilot Study in Critically Ill Neonates.2016PMID:25139979Permalink
No detected effect on retinopathy of prematurity incidence
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“No difference was found in the CYS and ISO groups with regards to the percent of subjects diagnosed with necrotizing enterocolitis (29% vs. 24%, p=1), intraventricular hemorrhage grade III and IV (19% vs. 24%, p=1), and need for laser treatment for retinopathy of prematurity (24% vs. 24%, p=1).”
Quoted verbatim from Effect of High-Dose Cysteine Supplementation on Erythrocyte Glutathione: A Double-Blinded, Randomized Placebo-Controlled Pilot Study in Critically Ill Neonates..
Study

RCT
Dose

cysteine-HCl 121 mg/kg/day in parenteral nutrition with sodium acetate 2 mEq/kg/day
Population

Critically ill neonates on mechanical ventilation and parenteral nutrition (SNAP > 10); event is ROP requiring laser treatment; comparator is isonitrogenous additional parenteral amino acids without cysteine
Effect of High-Dose Cysteine Supplementation on Erythrocyte Glutathione: A Double-Blinded, Randomized Placebo-Controlled Pilot Study in Critically Ill Neonates.2016PMID:25139979Permalink

What it touches on the way

Mechanistic reach

40 entities

40 entities reached.

0 reported hops40 assembled from the scaffold

Show the remaining 28

What the reference databases state

Statements

164 statements

164 statements · 3 reference databases · Subject: L-cysteine · Sources: ChEBI, Human-GEM, Rhea

Order

L-cysteine is converted to 2-oxo-3-sulfanylpropanoateCompoundRhea RHEA:17441Inferred only
L-cysteine is converted to 2-oxo-3-sulfanylpropanoateCompoundRhea RHEA:61256Inferred only
L-cysteine is converted to 2-oxo-3-sulfanylpropanoateCompoundHuman-GEM MAR03912Inferred only
2-oxo-3-sulfanylpropanoate is converted to L-cysteineCompoundRhea RHEA:61256Inferred only
L-cysteine is converted to 2-oxo-3-sulfanylpropanoateCompoundHuman-GEM MAR08684Inferred only
2-oxo-3-sulfanylpropanoate is converted to L-cysteineCompoundHuman-GEM MAR03912Inferred only
2-oxo-3-sulfanylpropanoate is converted to L-cysteineCompoundHuman-GEM MAR08684Inferred only
2-oxo-3-sulfanylpropanoate is converted to L-cysteineCompoundRhea RHEA:17441Inferred only
L-cysteine is converted to 3-sulfino-L-alanineCompoundRhea RHEA:20441Inferred only
L-cysteine is converted to 3-sulfino-L-alanineCompoundHuman-GEM MAR03908Inferred only
cysteamine is converted to L-cysteineCompoundRhea RHEA:27746Inferred only
L-cysteine is converted to cysteamineCompoundRhea RHEA:27746Inferred only

Show the remaining 152

L-cysteine is converted to D-cysteineCompoundRhea RHEA:59272Inferred only
D-cysteine is converted to L-cysteineCompoundRhea RHEA:59272Inferred only
L-cysteine is converted to gamma-L-glutamyl-L-cysteineCompoundHuman-GEM MAR04324Inferred only
L-cysteine is converted to gamma-L-glutamyl-L-cysteineCompoundRhea RHEA:13285Inferred only
hydrogen sulfide is converted to L-cysteineCompoundHuman-GEM MAR04323Inferred only
L-cysteine hydrochloride is converted to L-cysteineCompoundChEBI CHEBI:91247Inferred only
L-cystine is converted to L-cysteineCompoundHuman-GEM MAR03996Inferred only
L-cysteine is converted to L-cystineCompoundHuman-GEM MAR03995Inferred only
L-cysteine is converted to L-cystineCompoundHuman-GEM MAR03996Inferred only
L-cysteine is converted to L-cystineCompoundRhea RHEA:20597Inferred only
L-cystine is converted to L-cysteineCompoundRhea RHEA:20597Inferred only
L-cystine is converted to L-cysteineCompoundHuman-GEM MAR03995Inferred only
L-cysteine is a substrate of CARS1ProteinHuman-GEM MAR05135Inferred only
L-cysteine is a substrate of CARS1ProteinRhea RHEA:17773Inferred only
L-cysteine is a substrate of CARS2ProteinRhea RHEA:78627Inferred only
L-cysteine is a substrate of CARS2ProteinRhea RHEA:17773Inferred only
L-cysteine is a substrate of CARS2ProteinRhea RHEA:78543Inferred only
L-cysteine is a substrate of CDO1ProteinRhea RHEA:20441Inferred only
L-cysteine is a substrate of CDO1ProteinHuman-GEM MAR03908Inferred only
L-cysteine is a substrate of CISD1ProteinRhea RHEA:17441Inferred only
L-cysteine is a substrate of CTHProteinHuman-GEM MAR04302Inferred only
L-cysteine is a substrate of CTHProteinRhea RHEA:24931Inferred only
L-cysteine is a substrate of FDX2ProteinHuman-GEM MAR20185Inferred only
L-cysteine is a substrate of FDXRProteinHuman-GEM MAR20185Inferred only
L-cysteine is a substrate of FXNProteinHuman-GEM MAR20185Inferred only
L-cysteine is a substrate of GCLCProteinHuman-GEM MAR04324Inferred only
L-cysteine is a substrate of GCLCProteinRhea RHEA:13285Inferred only
L-cysteine is a substrate of GCLMProteinHuman-GEM MAR04324Inferred only
L-cysteine is a substrate of GOT1ProteinHuman-GEM MAR03912Inferred only
L-cysteine is a substrate of GOT1ProteinRhea RHEA:17441Inferred only
L-cysteine is a substrate of GOT2ProteinHuman-GEM MAR08684Inferred only
L-cysteine is a substrate of GOT2ProteinHuman-GEM MAR03912Inferred only
L-cysteine is a substrate of IFI30ProteinRhea RHEA:86267Inferred only
L-cysteine is a substrate of ISCUProteinHuman-GEM MAR20185Inferred only
L-cysteine is a substrate of LYRM4ProteinHuman-GEM MAR20185Inferred only
L-cysteine is a substrate of MOCOSProteinRhea RHEA:42636Inferred only
L-cysteine is a substrate of NAGSProteinHuman-GEM MAR05419Inferred only
L-cysteine is a substrate of NDUFAB1ProteinHuman-GEM MAR20185Inferred only
L-cysteine is a substrate of NFS1ProteinRhea RHEA:43892Inferred only
L-cysteine is a substrate of NFS1ProteinHuman-GEM MAR20185Inferred only
L-cysteine is a substrate of NFS1ProteinRhea RHEA:17457Inferred only
L-cysteine is a substrate of PPCSProteinHuman-GEM MAR04723Inferred only
L-cysteine is a substrate of PPCSProteinRhea RHEA:25156Inferred only
L-cysteine is a substrate of PPCSProteinHuman-GEM MAR11416Inferred only
L-cysteine is a substrate of PPCSProteinRhea RHEA:19397Inferred only
L-cysteine is a substrate of TXNRD1ProteinHuman-GEM MAR03995Inferred only
L-cysteine is a substrate of TXNRD2ProteinHuman-GEM MAR03995Inferred only
L-cysteine is a substrate of TXNRD3ProteinHuman-GEM MAR03995Inferred only
L-cysteine is transported by CLTRNProteinHuman-GEM MAR09876Inferred only
L-cysteine is transported by MFSD12ProteinRhea RHEA:29655Inferred only
L-cysteine is transported by SFXN1ProteinRhea RHEA:29655Inferred only
L-cysteine is transported by SLC1A1ProteinRhea RHEA:82559Inferred only
L-cysteine is transported by SLC1A4ProteinHuman-GEM MAR05609Inferred only
L-cysteine is transported by SLC1A4ProteinHuman-GEM MAR05709Inferred only
L-cysteine is transported by SLC1A4ProteinHuman-GEM MAR05639Inferred only
L-cysteine is transported by SLC1A4ProteinRhea RHEA:84347Inferred only
L-cysteine is transported by SLC1A4ProteinHuman-GEM MAR05717Inferred only
L-cysteine is transported by SLC1A4ProteinHuman-GEM MAR05790Inferred only
L-cysteine is transported by SLC1A4ProteinHuman-GEM MAR05710Inferred only
L-cysteine is transported by SLC1A4ProteinHuman-GEM MAR05719Inferred only
L-cysteine is transported by SLC1A4ProteinHuman-GEM MAR06377Inferred only
L-cysteine is transported by SLC1A4ProteinHuman-GEM MAR05708Inferred only
L-cysteine is transported by SLC1A5ProteinHuman-GEM MAR06377Inferred only
L-cysteine is transported by SLC1A5ProteinHuman-GEM MAR05609Inferred only
L-cysteine is transported by SLC1A5ProteinHuman-GEM MAR05790Inferred only
L-cysteine is transported by SLC1A5ProteinHuman-GEM MAR05760Inferred only
L-cysteine is transported by SLC1A5ProteinHuman-GEM MAR05719Inferred only
L-cysteine is transported by SLC1A5ProteinHuman-GEM MAR05717Inferred only
L-cysteine is transported by SLC1A5ProteinHuman-GEM MAR05710Inferred only
L-cysteine is transported by SLC1A5ProteinHuman-GEM MAR05709Inferred only
L-cysteine is transported by SLC1A5ProteinHuman-GEM MAR05639Inferred only
L-cysteine is transported by SLC1A5ProteinHuman-GEM MAR05624Inferred only
L-cysteine is transported by SLC38A1ProteinRhea RHEA:68232Inferred only
L-cysteine is transported by SLC38A4ProteinHuman-GEM MAR06377Inferred only
L-cysteine is transported by SLC38A4ProteinRhea RHEA:68232Inferred only
L-cysteine is transported by SLC38A5ProteinRhea RHEA:71171Inferred only
L-cysteine is transported by SLC38A5ProteinHuman-GEM MAR06887Inferred only
L-cysteine is transported by SLC3A1ProteinHuman-GEM MAR05979Inferred only
L-cysteine is transported by SLC3A1ProteinHuman-GEM MAR05931Inferred only
L-cysteine is transported by SLC3A1ProteinHuman-GEM MAR05550Inferred only
L-cysteine is transported by SLC3A1ProteinHuman-GEM MAR05915Inferred only
L-cysteine is transported by SLC3A1ProteinHuman-GEM MAR05963Inferred only
L-cysteine is transported by SLC3A1ProteinHuman-GEM MAR05947Inferred only
L-cysteine is transported by SLC3A2ProteinHuman-GEM MAR05492Inferred only
L-cysteine is transported by SLC3A2ProteinHuman-GEM MAR05465Inferred only
L-cysteine is transported by SLC3A2ProteinHuman-GEM MAR05084Inferred only
L-cysteine is transported by SLC43A1ProteinHuman-GEM MAR05084Inferred only
L-cysteine is transported by SLC6A14ProteinRhea RHEA:71319Inferred only
L-cysteine is transported by SLC6A14ProteinHuman-GEM MAR09599Inferred only
L-cysteine is transported by SLC6A15ProteinRhea RHEA:68232Inferred only
L-cysteine is transported by SLC6A15ProteinHuman-GEM MAR06377Inferred only
L-cysteine is transported by SLC6A18ProteinHuman-GEM MAR09876Inferred only
L-cysteine is transported by SLC6A19ProteinRhea RHEA:68232Inferred only
L-cysteine is transported by SLC6A19ProteinHuman-GEM MAR06377Inferred only
L-cysteine is transported by SLC7A10ProteinRhea RHEA:74031Inferred only
L-cysteine is transported by SLC7A10ProteinHuman-GEM MAR05492Inferred only
L-cysteine is transported by SLC7A10ProteinHuman-GEM MAR05084Inferred only
L-cysteine is transported by SLC7A3ProteinHuman-GEM MAR05084Inferred only
L-cysteine is transported by SLC7A5ProteinHuman-GEM MAR05479Inferred only
L-cysteine is transported by SLC7A5ProteinHuman-GEM MAR05504Inferred only
L-cysteine is transported by SLC7A5ProteinHuman-GEM MAR05654Inferred only
L-cysteine is transported by SLC7A5ProteinHuman-GEM MAR05669Inferred only
L-cysteine is transported by SLC7A5ProteinHuman-GEM MAR05465Inferred only
L-cysteine is transported by SLC7A5ProteinHuman-GEM MAR05515Inferred only
L-cysteine is transported by SLC7A5ProteinHuman-GEM MAR05525Inferred only
L-cysteine is transported by SLC7A5ProteinHuman-GEM MAR05534Inferred only
L-cysteine is transported by SLC7A5ProteinHuman-GEM MAR05542Inferred only
L-cysteine is transported by SLC7A5ProteinHuman-GEM MAR05594Inferred only
L-cysteine is transported by SLC7A5ProteinHuman-GEM MAR05492Inferred only
L-cysteine is transported by SLC7A5ProteinHuman-GEM MAR05084Inferred only
L-cysteine is transported by SLC7A5ProteinHuman-GEM MAR05556Inferred only
L-cysteine is transported by SLC7A5ProteinHuman-GEM MAR05551Inferred only
L-cysteine is transported by SLC7A5ProteinHuman-GEM MAR05555Inferred only
L-cysteine is transported by SLC7A5ProteinHuman-GEM MAR05552Inferred only
L-cysteine is transported by SLC7A5ProteinHuman-GEM MAR05553Inferred only
L-cysteine is transported by SLC7A5ProteinHuman-GEM MAR05554Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05711Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05715Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05716Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05707Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05709Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05699Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05979Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05712Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05639Inferred only
L-cysteine is transported by SLC7A6ProteinRhea RHEA:70847Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05721Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05730Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05624Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05963Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05820Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05867Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05868Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05869Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05870Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05871Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05594Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05931Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05915Inferred only
L-cysteine is transported by SLC7A6ProteinHuman-GEM MAR05947Inferred only
L-cysteine is transported by SLC7A7ProteinHuman-GEM MAR05084Inferred only
L-cysteine is transported by SLC7A8ProteinHuman-GEM MAR05465Inferred only
L-cysteine is transported by SLC7A8ProteinHuman-GEM MAR05084Inferred only
L-cysteine is transported by SLC7A8ProteinRhea RHEA:71055Inferred only
L-cysteine is transported by SLC7A8ProteinRhea RHEA:71031Inferred only
L-cysteine is transported by SLC7A9ProteinHuman-GEM MAR05550Inferred only
L-cysteine is transported by SLC7A9ProteinHuman-GEM MAR05915Inferred only
L-cysteine is transported by SLC7A9ProteinHuman-GEM MAR05931Inferred only
L-cysteine is transported by SLC7A9ProteinHuman-GEM MAR05947Inferred only
L-cysteine is transported by SLC7A9ProteinHuman-GEM MAR05963Inferred only
L-cysteine is transported by SLC7A9ProteinHuman-GEM MAR05979Inferred only
L-cysteine is transported by SLC7A9ProteinRhea RHEA:71071Inferred only

Reactions

220 reactions

L-alanine+L-arginine+L-asparagine+L-aspartate+CHEBI:1307929+a cholesterol ester+a cardiolipin+MAM01602c+L-cysteine+MAM01721n+MAM01722n+L-glutamate(1-)+L-glutamine+glycine+CHEBI:15971+L-isoleucine+L-leucine+MAM02392c+CHEBI:18019+L-methionine+L-phenylalanine+phosphatidic acid+1-phosphatidyl-1D-myo-inositol+CHEBI:17203+MAM02847c+L-seryl residue+a sphingomyelin+CHEBI:16857+L-tryptophan+CHEBI:17895+L-valine+MAM03161cMAM03970c
Reaction pageBlockedBalance undeterminablecytosol, endoplasmic reticulum, nucleus
Human-GEM MAR00021CC BY 4.0Reference data
water+L,L-cystathionine2-oxobutanoate+L-cysteine+proton+ammonium
Catalysed by CTH
Reaction pageLeft to rightBalancedEC 4.4.1.1cytosol
Human-GEM MAR03881CC BY 4.0Reference data
L-cysteine+dioxygen3-sulfino-L-alanine+2proton
Catalysed by CDO1
Reaction pageLeft to rightBalancedEC 1.13.11.20cytosol
Human-GEM MAR03908CC BY 4.0Reference data
2-oxoglutarate(2-)+L-cysteineL-glutamate(1-)+2-oxo-3-sulfanylpropanoate
Catalysed by GOT1 or GOT2
Reaction pageReversibleBalancedEC 2.6.1.1, 2.6.1.3cytosol
Human-GEM MAR03912CC BY 4.0Reference data
L-cystine+proton+NADPH(4-)2L-cysteine+NADP(3-)
Catalysed by TXNRD2 or TXNRD3 or TXNRD1
Reaction pageReversibleBalancedEC 1.8.1.9cytosol
Human-GEM MAR03995CC BY 4.0Reference data
L-cystine+proton+NADH(2-)2L-cysteine+NAD(+)
Reaction pageReversibleBalancedEC 1.8.1.6cytosol
Human-GEM MAR03996CC BY 4.0Reference data
L-cysteine+water2proton+hydrogen sulfide+ammonium+pyruvate
Catalysed by CTH
Reaction pageLeft to rightBalancedEC 4.4.1.1, 4.4.1.13cytosol
Human-GEM MAR04302CC BY 4.0Reference data
proton+hydrogen sulfide+L-seryl residueL-cysteine+water
Catalysed by CBS
Reaction pageLeft to rightBalancedEC 4.2.1.22cytosol
Human-GEM MAR04323CC BY 4.0Reference data
ATP+L-cysteine+L-glutamate(1-)ADP+gamma-L-glutamyl-L-cysteine+proton+phosphate(3-)
Catalysed by GCLC & GCLM
Reaction pageLeft to rightBalancedEC 6.3.2.2cytosol
Human-GEM MAR04324CC BY 4.0Reference data
L-cysteinylglycine+waterL-cysteine+glycine
Catalysed by LAP3 or NPEPPS or ANPEP
Reaction pageLeft to rightBalancedEC 3.4.11.1, 3.4.11.2cytosol
Human-GEM MAR04328CC BY 4.0Reference data
L-cysteinylglycine+waterL-cysteine+glycine
Catalysed by LAP3 or NPEPPS or ANPEP
Reaction pageLeft to rightBalancedEC 3.4.11.1, 3.4.11.2extracellular space
Human-GEM MAR04329CC BY 4.0Reference data
0.505626L-alanine+0.35926L-arginine+0.279425L-asparagine+0.352607L-aspartate+20.704451ATP+0.020401CHEBI:1307929+0.011658a cardiolipin+0.039036CHEBI:17677+0.046571L-cysteine+0.013183CHEBI:16284+0.009442dCTP+0.009898CHEBI:16497+0.013091dTTP+0.275194D-glucopyranose 6-phosphate+0.385872L-glutamate(1-)+0.325996L-glutamine+0.538891glycine+0.036117GTP+20.650823water+0.126406CHEBI:15971+0.286078L-isoleucine+0.545544L-leucine+0.592114CHEBI:18019+0.153018L-methionine+0.1544631,2-diacyl-sn-glycero-3-phosphocholine(1+)+0.055374phosphatidylethanolamine+0.002914MAM02715c+0.259466L-phenylalanine+0.0233151-phosphatidyl-1D-myo-inositol+0.412484CHEBI:17203+0.005829phosphatidyl-L-serine+0.392525L-seryl residue+0.017486a sphingomyelin+0.31269CHEBI:16857+0.013306L-tryptophan+0.159671CHEBI:17895+0.053446UTP+0.352607L-valine20.650823ADP+20.650823proton+20.650823phosphate(3-)+MAM03970c
Reaction pageBlockedBalance undeterminablecytosol, nucleus
Human-GEM MAR04413CC BY 4.0Reference data

Show the remaining 208

On the label

Labelled products

253 products

Source: NIH DSLD · Ingredient: L-cysteine · 253 products · Declared amount per serving: 1–1,500 mg (244 products)

252 labels state an amount1 does not

Order

1MD NutritionBreatheMDL-Cysteine Hydrochloride600 mgper 2 Capsule(s)DSLD:309804
21st CenturyDaily Amino AcidL-Cysteine Hydrochloride11 mgper 1 Tablet(s)DSLD:258438
21st CenturyHair, Skin & Nails3.5 mgper 1 Tablet(s)DSLD:205740
AB American BiologicsOxy-5000 Forte10 mgper 2 Tablet(s)DSLD:20260
AB American BiologicsOxy-5000 Forte10 mgper 2 Tablet(s)DSLD:20268
AB American BiologicsOxy-5000 Forte10 mgper 2 Tablet(s)DSLD:20269
AB American BiologicsUltra Inf-Zyme Forte10 mgper 1 Tablet(s)DSLD:20341
Akasha NaturalsUltraCleanse PlusL-Cysteine Hydrochloride85 mgper 42 Gram(s)DSLD:313121
Allergy Research GroupAmino Acid Neurotransmitter Formula37 mgper 4 Gram(s)DSLD:54247
AntioxidantTechFinura375 mgper 1 Tablet(s)DSLD:339188
Approved ScienceHairprin200 mgper 1 Capsule(s)DSLD:319769
Approved ScienceJointprin +BioPerineL-Cysteine Hydrochloride9.8 mgper 3 Tablet(s)DSLD:319778

Show the remaining 241

Biotics Research CorporationAmino Sport42 mgper 3 Capsule(s)DSLD:21470
Biotics Research CorporationBio-Detox PacksL-Cysteine Hydrochloride · Cysteine (Form: as L-Cysteine HCl)10 mcgper 1 Packet(s)DSLD:21771
Biotics Research CorporationBromelain PlusL-Cysteine Hydrochloride · Cysteine (Form: as L-cysteine hydrochloride)5 mgper 1 Tablet(s)DSLD:21528
Biotics Research CorporationBromelain Plus CLAL-Cysteine Hydrochloride · Cysteine (Form: as L-Cysteine Hydrochloride)5 mgper 1 Tablet(s)DSLD:21518
Body Attack Sports Nutrition100% Whey Protein ApfelstrudelAmino Acid Profile2.39 Gram(s)per 30 Gram(s)DSLD:329523
Bronson30 Day Beauty Regimen10 mgper 3 Tablet(s)DSLD:7000
Bronson LaboratoriesSkin, Hair & NailsL-Cysteine Hydrochloride Monohydrate50 mgper 1 Capsule(s)DSLD:25071
BulkSupplements.comL-Cystine500 mgper 500 mgDSLD:312134
BulkSupplements.comL-Cystine500 mgper 500 mgDSLD:312135
BulkSupplements.comL-Cystine500 mgper 500 mgDSLD:312136
BulkSupplements.comL-Cystine500 mgper 500 mgDSLD:312137
Burbank Glendale ChiropracticUltimate Health Complex50 mgper 2 Tablet(s)DSLD:22089
Buried Treasure Liquid NutrientsHair Skin & Nails100 mgper 15 mLDSLD:250656
California Academy of HealthWhey Protein Gold Isolate Plus Natural Chocolate Flavor458 mgper 44 Gram(s)DSLD:191162
California Academy of HealthWhey Protein Gold Isolate Plus Natural Vanilla Flavor504 mgper 6 TbspDSLD:197375
California Gold NutritionHair Multivitamin10 mgper 2 Capsule(s)DSLD:299619
California Gold NutritionHair Multivitamin10 mgper 2 Capsule(s)DSLD:299620
California Gold NutritionL-Cysteine 500 mg500 mgper 1 Capsule(s)DSLD:299638
CHK NutritionHair, Skin & Nails300 mgper 3 Tablet(s)DSLD:252936
Consumer HealthJointlaxL-Cysteine Hydrochloride9.8 mgper 3 Tablet(s)DSLD:277123
D'Adamo Personalized NutritionDeflect O100 mgper 2 Capsule(s)DSLD:287134
DaVinci LaboratoriesAmino 2122.5 mgper 1 Capsule(s)DSLD:322151
DaVinci LaboratoriesHair Effects200 mgper 3 Capsule(s)DSLD:322171
DaVinci LaboratoriesSpectra50 mgper 2 Tablet(s)DSLD:304038
DaVinci LaboratoriesSpectra50 mgper 2 Tablet(s)DSLD:304039
DaVinci LaboratoriesSpectra ManEnteric coated50 mgper 2 Tablet(s)DSLD:313253
DaVinci LaboratoriesSpectra Man50 mgper 2 Tablet(s)DSLD:313254
DaVinci LaboratoriesSpectra Senior25 mgper 3 Tablet(s)DSLD:304045
DaVinci LaboratoriesSpectra Woman50 mgper 2 Tablet(s)DSLD:305242
DaVinci LaboratoriesSpectra Woman50 mgper 2 Tablet(s)DSLD:322207
DaVinci LaboratoriesSpectra Woman50 mgper 2 Tablet(s)DSLD:322208
DaVinci LaboratoriesUltimate PrenatalEnteric Coated20 mgper 5 Tablet(s)DSLD:304055
DaVinci Laboratories Of VermontCell SupportL-Cysteine Note: Enteric Coated50 mgper 2 Capsule(s)DSLD:22005
DaVinci Laboratories Of VermontGenessentials OS-1L-Cysteine Note: Enteric Coated50 mgper 2 Capsule(s)DSLD:22710
DaVinci Laboratories Of VermontGenessentials OS-1L-Cysteine Note: Enteric Coated50 mgper 2 Capsule(s)DSLD:22712
DaVinci Laboratories Of VermontSpectra Without Copper And Iron50 mgper 2 Tablet(s)DSLD:23690
DCVision GardL-Cysteine Hydrochloride30 mgper 1 Capsule(s)DSLD:266807
DCVision MaxxL-Cysteine Hydrochloride60 mgper 2 Capsule(s)DSLD:266024
DCVision MaxxL-Cysteine Hydrochloride · L-Cysteine (Form: as L-Cysteine Hydrochloride)60 mgper 2 Capsule(s)DSLD:267237
DCVision MaxxL-Cysteine Hydrochloride60 mgper 2 Capsule(s)DSLD:267238
DCVision MaxxL-Cysteine Hydrochloride60 mgper 2 Capsule(s)DSLD:309926
Designs for HealthPaleoCleanse Functional Detoxification Powder125 mgper 18 Gram(s)DSLD:23240
DEVAVegan Hair Nails & SkinFermentation Source50 mgper 1 Tablet(s)DSLD:304311
Douglas LaboratoriesAdded Protection IIIL-Cysteine Hydrochloride · Cysteine (Form: as L-cysteine hydrochloride)250 mgper 6 Tablet(s)DSLD:31289
Douglas LaboratoriesAmino Gram Forte10 mgper 1 Tablet(s)DSLD:57724
Douglas LaboratoriesArthro-SynSulfur75 mgper 4 Capsule(s)DSLD:8127
Douglas LaboratoriesL-Cysteine 500 mg500 mgper 1 Capsule(s)DSLD:8699
Douglas LaboratoriesRedox150 mgper 2 Capsule(s)DSLD:9431
Douglas LaboratoriesUltra Preventive Forte-Chel190 mgper 9 Tablet(s)DSLD:10212
Douglas LaboratoriesUltra Preventive Forte-Chel190 mgper 9 Tablet(s)DSLD:31024
Douglas LaboratoriesUltra Preventive Forte-Chel (Capsules)190 mgper 15 Capsule(s)DSLD:10186
Douglas LaboratoriesUltra Protein Plus Natural Vanilla Bean Flavor220 mgper 31.6 Gram(s)DSLD:30694
Douglas LaboratoriesUltra-Guard Low Allergenicity Antioxidant200 mgper 1 Tablet(s)DSLD:8705
Douglas LaboratoriesVita Chel Pack350 mgper 1 Packet(s)DSLD:8861
Douglas LaboratoriesVita-Big Kids48 mgper 6 Capsule(s)DSLD:10215
Douglas LaboratoriesVita-Chel Plus300 mgper 6 Tablet(s)DSLD:9412
Douglas LaboratoriesVita-Chel Plus300 mgper 6 Tablet(s)DSLD:9413
Douglas LaboratoriesVita-Chel Plus300 mgper 6 Tablet(s)DSLD:9416
Dr. Clark Research Association Dr. Clark ZentrumCysteine 500 mg1,500 mgper 1 Capsule(s)DSLD:223490
Dr. Clark Research Association Dr. Clark ZentrumEssential Amino Acids 500 mg72 mgper 6 Capsule(s)DSLD:223131
Dr. Clark StoreCysteine 500 mg500 mgper 1 Capsule(s)DSLD:219829
Dr. Rico PerezAmino ComplexL-Cysteine Hydrochloride8 mgper 1 Capsule(s)DSLD:321008
Dr. Rico PerezHair, Skin & NailsL-Cysteine Hydrochloride50 mgper 2 Capsule(s)DSLD:321058
Drucker LabsintraMAX 2.0 Peach Mango Flavoramount not statedper 1 fl. Oz.DSLD:236722
ecoNugenicsDetox CompleteL-Cysteine Hydrochloride · Cysteine (Form: as L-Cysteine HCl)167 mgper 1 Capsule(s)DSLD:22420
elonMatrix 5,000 Complete50 mgper 1 Tablet(s)DSLD:248469
elonMatrix 5000 Complete50 mgper 1 Tablet(s)DSLD:248453
ElonMatrix Plus 3000Cysteine Hydrochloride50 mgper 1 Tablet(s)DSLD:319977
Enriching GiftsAmino Acids4 mgper 2 Capsule(s)DSLD:228176
Esmond NaturalHair, Skin & Nails30 mgper 1 Caplet(s)DSLD:334331
Esmond NaturalMen's Vitality Complex50 mgper 1 Tablet(s)DSLD:230788
EvinceNaturalsWomen's Daily Nutritional SystemL-Cysteine Monohydrate Hydrochloride · Cysteine (Form: as L-Cysteine Monohydrate HCl)5 mgper 5 Capsule(s)DSLD:229474
ForeverForever VisionN-Acetyl Cysteine · Cysteine (Form: as N-Acetyl Cysteine)50 mgper 2 Tablet(s)DSLD:70433
Garden of LifeOrgan DetoxSaccharomyces cerevisiae28 mgper 3 Capsule(s)DSLD:321361
Garden of LifeRaw Cleanse Organ DetoxSaccharomyces cerevisiae28 mgper 3 Capsule(s)DSLD:273825
GenesaTotal Amino SolutionN-Acetyl Cysteine · Cysteine (Form: as N-Acetyl-L-Cysteine)90 mgper 3 Vegi-Capsule(s)DSLD:205996
Genestra BrandsGlucosamine ComplexL-Cysteine Hydrochloride Monohydrate · L-Cysteine (Form: as L-Cysteine Hydrochloride Monohydrate)50 mgper 2 Capsule(s)DSLD:241144
Genestra BrandsGlucosamine ComplexL-Cysteine Hydrochloride Monohydrate50 mgper 2 Capsule(s)DSLD:306028
Genestra BrandsMaxum Multi ViteL-Cysteine Hydrochloride10 mgper 1 Capsule(s)DSLD:288555
Genestra BrandsMaxum Multi ViteL-Cysteine Hydrochloride10 mgper 1 Capsule(s)DSLD:288556
Genestra BrandsSuper Orti ViteCysteine Hydrochloride10 mgper 1 Capsule(s)DSLD:288559
GNC Men'sUltra NourishHair100 mgper 2 Caplet(s)DSLD:243513
GNC Men'sUltra NourishHair100 mgper 2 Caplet(s)DSLD:76009
GNC Women'sAdvanced Collagen Formula19 mgper 1 Capsule(s)DSLD:79168
GNC Women'sHair, Skin & Nails200 mgper 2 Caplet(s)DSLD:229164
GNC Women'sHair, Skin & Nails Beauty Basics200 mgper 2 Caplet(s)DSLD:229169
GNC Women'sHair, Skin & Nails Beauty Basics200 mgper 2 Caplet(s)DSLD:243688
GNC Women'sHair, Skin & Nails Formula200 mgper 2 Caplet(s)DSLD:26993
GNC Women'sHair, Skin & Nails Formula200 mgper 2 Tablet(s)DSLD:69529
GNC Women'sHair, Skin & Nails Formula200 mgper 2 Tablet(s)DSLD:75150
GNC Women'sHair, Skin & Nails Formula200 mgper 2 Caplet(s)DSLD:79158
GNC Women'sUltra NourishHair Beauty Basics200 mgper 2 Caplet(s)DSLD:229228
GNC Women'sUltra NourishHair Beauty Basics200 mgper 2 Caplet(s)DSLD:229202
Health Products Distributors, Inc.Chewable Kids Mighty-Multi Tasty Fruit Flavor!L-Cysteine Hydrochloride Monohydrate5 mgper 2 Tablet(s)DSLD:321330
Healthy Choice NaturalsHair, Skin, & Nail essentials200 mgper 1 Capsule(s)DSLD:16991
Healthy ItemsCardio-CareCysteine Hydrochloride200 mgper 4 Capsule(s)DSLD:183338
Higher NaturePerformax Sports5 mgper 1 Tablet(s)DSLD:42267
Higher NatureSuper Antioxidant5 mgper 1 Tablet(s)DSLD:40916
Higher NatureSuper Antioxidant5 mgper 1 Tablet(s)DSLD:41031
Higher NatureSuper Antioxidant Complex10 mgper 1 Tablet(s)DSLD:275915
Higher NatureSuper Antioxidant Protection10 mgper 1 Tablet(s)DSLD:228425
Higher NatureSuper Antioxidant Protection5 mgper 1 Tablet(s)DSLD:240564
Higher NatureSuper Antioxidant Protection10 mgper 1 Tablet(s)DSLD:245830
Higher NatureSuper Antioxidant Protection5 mgper 1 Tablet(s)DSLD:41291
Higher NatureSuper Antioxidant Protection5 mgper 1 Tablet(s)DSLD:41293
Home HealthPre-Natal Multi-Vitamin Multi-Mineral SupplementL-Cysteine Note: Enteric Coated8 mgper 2 Tablet(s)DSLD:19369
Integrative TherapeuticsCurcumax25 mgper 1 Capsule(s)DSLD:77086
Integrative TherapeuticsDerma Care With Proprietary Omega Blend10 mgper 2 Softgel(s)DSLD:23903
Integrative TherapeuticsInflamzyme75 mgper 1 Tablet(s)DSLD:24106
Integrative TherapeuticsRecancostat 10040 mgper 1 Capsule(s)DSLD:78447
Integrative TherapeuticsRecancostat Powder Unflavored140 mgper 1.2 Gram(s)DSLD:78366
InterPlexusPoly VytaMyns152 mgper 2 Capsule(s)DSLD:271541
InterPlexus Whole Body HealthThyro-DyneL-Cysteine Hydrochloride210 mgper 2 Capsule(s)DSLD:337411
Just ThriveGut 4-tify40 mgper 3 Capsule(s)DSLD:319891
KALHair Force500 mgper 3 VegCap(s)DSLD:322909
Lake Avenue NutritionL-Cysteine 500 mg500 mgper 1 Capsule(s)DSLD:319359
Leading Edge HealthProfollica Plus with Millet Extract6 mcgper 2 Veggie Capsule(s)DSLD:272171
LES LabsLiver Support200 mgper 2 Capsule(s)DSLD:276521
Life ExtensionWinter Wellness700 mgper 2 Capsule(s)DSLD:59062
LifeSeasons TherapeuticsBeau-T50 mgper 3 Capsule(s)DSLD:310461
LifeTIMESupreme Vital Hair with MSML-Cysteine Hydrochloride200 mgper 4 Capsule(s)DSLD:268492
Logos NutritionalsFabulous Hair100 mcgper 2 Tablet(s)DSLD:335710
LuckyVitaminL-Cysteine 500 mgL-Cysteine Hydrochloride500 mgper 1 Tablet(s)DSLD:283206
Martin Avenue PharmacyAmino Acids Formula10 mgper 1 Tablet(s)DSLD:18766
Martin Avenue PharmacyNSAID Rx Depletion5 mgper 2 Capsule(s)DSLD:19468
MetagenicsGI SustainL-Cysteine Hydrochloride25 mgper 49 Gram(s)DSLD:323360
MetagenicsGut Care for Kids Pineapple Flavour200 mgper 5 Gram(s)DSLD:305328
MetagenicsImmune Defense Pack8 mgper 1 Packet(s)DSLD:295900
MetagenicsUltra Potent-C 10008 mgper 1 Tablet(s)DSLD:295870
MetagenicsUltra Potent-C 5004 mgper 1 Tablet(s)DSLD:295871
MetagenicsUltra Potent-C Chewable Natural Orange Blast Flavor2 mgper 1 Tablet(s)DSLD:295872
MetagenicsUltra Potent-C Powder11 mgper 1.95 Gram(s)DSLD:295873
MetagenicsUltraClear Plus Natural Berry FlavorL-Cysteine Hydrochloride85 mgper 22 Gram(s)DSLD:265119
MetagenicsUltraClear Plus pH Vanilla FlavorL-Cysteine Hydrochloride85 mgper 11 Gram(s)DSLD:295874
MetagenicsUltraClear Plus Vanilla FlavorL-Cysteine Hydrochloride85 mgper 10.5 Gram(s)DSLD:295875
Natural Factors WS WomenSenseHair, Skin & NailsL-Cysteine Hydrochloride Monohydrate150 mgper 4 Vegetarian Capsule(s)DSLD:76195
Nature's AnswerLiquid Hair Skin & Nails100 mgper 1 TbspDSLD:63271
Nature's SunshineFree Amino Acids21 mgper 2 Tablet(s)DSLD:255231
NaturesPlusHema-Plex CapsulesL-Cysteine Note: free from Amino Acid50 mgper 2 Capsule(s)DSLD:319184
NaturesPlusHema-Plex Liquid Delicious Mixed Berry FlavorL-Cysteine Note: free form amino acid30 mgper 5 mLDSLD:319185
NaturesPlusHema-Plex Softgelsfree form amino acid50 mgper 3 Softgel(s)DSLD:319186
NaturesPlusHema-Plex Tabletsfree form amino acid50 mgper 1 Tablet(s)DSLD:318926
NaturesPlusHema-Plex Tabletsfree form amino acid50 mgper 1 Tablet(s)DSLD:322625
NaturesPlusImmunacefree form amino acid200 mgper 2 Tablet(s)DSLD:298459
NaturesPlusImmune Support150 mgper 2 Tablet(s)DSLD:248825
NaturesPlusMen's Ultra Hair Plusfree form amino acid100 mgper 2 Tablet(s)DSLD:318932
NaturesPlusUltra Hairfree form amino amino acid100 mgper 2 Tablet(s)DSLD:320526
NaturesPlusUltra Hairfree form amino acid100 mgper 2 Tablet(s)DSLD:322626
NaturesPlusUltra Hairfree form amino amino acid100 mgper 4 Tablet(s)DSLD:322627
NaturesPlusUltra Hair Plus with MSMfree form amino acid100 mgper 2 Tablet(s)DSLD:320527
NaturesPlusWomen's Ultra Hair PlusL-Cysteine Note: free form amino acid100 mgper 2 Tablet(s)DSLD:250532
NaturesPlus AgeLossBlood Pressure SupportL-Cysteine Note: free form amino acid50 mgper 3 Tablet(s)DSLD:249509
NaturesPlus AgeLossHair SupportL-Cysteine Note: free form amino acid100 mgper 3 Extended Release Tablet(s)DSLD:252189
NeoLife NutritionalsCoQ10 Mitochondrial Energy Complex50 mgper 2 Softgel(s)DSLD:303277
New NordicHair Volume plus Nail Strong60 mgper 2 Tablet(s)DSLD:211706
New SunUltra Chel160 mgper 4 Tablet(s)DSLD:32288
NewtonEverettAminoForce8 mgper 1 Capsule(s)DSLD:292148
NorthStar NutritionalsRestore FX200 mgper 3 Softgel(s)DSLD:277281
Nutra BioGenesisBioCleanse PlusL-Cysteine Hydrochloride9.8 mgper 34.8 Gram(s)DSLD:322982
NutraBio100% Pure L-Cysteine 500 Milligrams500 mgper 1 Vegetable Capsule(s)DSLD:51131
Nutri-WestCardio-Lyph Chelate41 mgper 1 Tablet(s)DSLD:27579
Nutri-WestCore Level Adrenal 60 Tablets10 mgper 1 Tablet(s)DSLD:27702
Nutri-WestCore Level Bile10 mgper 1 Tablet(s)DSLD:27716
Nutri-WestCore Level Thiamine10 mgper 1 Tablet(s)DSLD:27745
Nutri-WestDSF-Herbal1 mgper 1 Tablet(s)DSLD:27685
Nutri-WestTotal Joint Support50 mgper 1 Tablet(s)DSLD:28496
Nutri-WestTotal Joint Support50 mgper 1 Tablet(s)DSLD:28497
NutriCologySuper Immuno Complex14 mgper 1 Packet(s)DSLD:183928
Nutrients for HealthUltimate Antioxidant10 mgper 2 Caplet(s)DSLD:316942
OmniLifePowerMaker3.04 Gram(s)per 10 Gram(s)DSLD:208655
Pharmaxa LabsNufolixL-Cysteine Hydrochloride50 mgper 2 Tablet(s)DSLD:321345
PL Progressive LaboratoriesOne Step Unflavored175 mgper 32 Gram(s)DSLD:299206
PlexusIronwoman100 mgper 1 Capsule(s)DSLD:321198
Premium CertifiedRootMD200 mgper 1 Capsule(s)DSLD:308066
Priority One Nutritional SupplementsOxi-Plus99 mgper 1 Capsule(s)DSLD:310769
ProCapsEssential Amino Protein25 mgper 4 Capsule(s)DSLD:331548
Progressive Professional from Progressive LaboratoriesAmino Blend23 mgper 3 Capsule(s)DSLD:261202
Progressive Professional from Progressive LaboratoriesCardio Clear167 mgper 2 Capsule(s)DSLD:261474
Progressive Professional from Progressive LaboratoriesGC-MSM 3550100 mgper 4 Capsule(s)DSLD:261763
Progressive Professional from Progressive LaboratoriesOne Step Chocolate Flavor175 mgper 39 Gram(s)DSLD:299243
Puritan's PrideUltra Man MaxL-Cysteine Hydrochloride50 mgper 2 Caplet(s)DSLD:318336
Puritan's Pride PremiumHealthy Hair FormulaL-Cysteine Note: 1 g1,000 mgper 3 Capsule(s)DSLD:239818
Puritan's Pride PremiumL-Cysteine 500 mgL-Cysteine Free Form500 mgper 1 Capsule(s)DSLD:285038
Rag Tag HealthNatural Born Hair RaiserL-Cysteine Hydrochloride150 mgper 2 Capsule(s)DSLD:35292
Rise-N-ShineHair Vitamins50 mcgper 1 Tablet(s)DSLD:297085
Rite Aid PharmacyHair, Skin & Nails200 mgper 2 Tablet(s)DSLD:45302
Seeking HealthOptimal Amino Blend26 mgper 1 Capsule(s)DSLD:210883
SeniorLife HealthJoint Health Essentials50 mgper 2 Capsule(s)DSLD:2172
Signature SupplementsBeautiful Skin & Nails100 mgper 2 Capsule(s)DSLD:338612
Signature SupplementsHair Boost For Women300 ngper 2 Capsule(s)DSLD:338774
SolarayL-Cysteine 500 mg500 mgper 1 VegCap(s)DSLD:338447
SolumevePearl Tomato 400 mg25 mgper 1 Capsule(s)DSLD:299025
Sonora NutritionMultivitamin for Men100 mgper 3 Capsule(s)DSLD:247436
Source NaturalsL-Cysteine PowderL-Cysteine Hydrochloride Monohydrate900 mgper 1.2 Gram(s)DSLD:274767
Source NaturalsLustreL-Cysteine Hydrochloride133 mgper 2 Tablet(s)DSLD:295964
Source NaturalsWellness D-mmunity 125 MCG50 mgper 2 Capsule(s)DSLD:296375
SteelVeg-Pro Vanilla Cream Pie422 mgper 1 Scoop(s)DSLD:218137
SuperSmartGrey Hair Formula150 mgper 3 Capsule(s)DSLD:332370
SuperSmartHair & Nails Formula120 mgper 2 Capsule(s)DSLD:332374
Supplement SpotMaximum Hair50 mgper 1 Tablet(s)DSLD:310055
Supplement SpotMaximum Nails50 mgper 1 Tablet(s)DSLD:310056
SwansonHair Revitalizing FormulaL-Cysteine Hydrochloride100 mgper 1 Tablet(s)DSLD:337831
SwansonHair, Skin & NailsL-Cysteine Hydrochloride100 mgper 1 Tablet(s)DSLD:265635
Terry NaturallyHair Renew Formula100 mgper 1 Softgel(s)DSLD:304504
The Professional SeriesNSAID Support5 mgper 2 Capsule(s)DSLD:10732
ThorneAmino Complex Lemon Flavored150 mgper 7.7 Gram(s)DSLD:323098
ThorneAmino Complex Lemon Flavored150 mgper 7.7 Gram(s)DSLD:336309
Trace NutrientsMin-Plex BL-Cysteine Hydrochloride · Cysteine (Form: as L-Cysteine HCl)3 mgper 1 Tablet(s)DSLD:74006
TriVitaLeanology Chocolate168 mgper 30.3 Gram(s)DSLD:33082
TruehopeAminopowerplusN-Acetyl Cysteine Hydrochloride · Cysteine (Form: as N-Acetyl-L-Cysteine Hydrochloride)31.2 mgper 4 Veggie Capsule(s)DSLD:32348
TwinlabAmino Fuel 1000111 mgper 4 Tablet(s)DSLD:73907
Ultimate Nutrition Platinum SeriesAnti-OxidantL-Cysteine Hydrochloride Monohydrate200 mgper 1 Tablet(s)DSLD:293447
USANAHealthPak80 mgper 1 Packet(s)DSLD:322317
USANAHepasil DTX225 mgper 3 Tablet(s)DSLD:322318
USANAPrenatal Core Minerals80 mgper 2 Tablet(s)DSLD:322324
Vigor LabsWolf's Mane100 mcgper 2 Tablet(s)DSLD:334348
VitabaseGreat Hair100 mgper 2 Tablet(s)DSLD:5984
VitalBulkVitalShake30 mgper 44 Gram(s)DSLD:233539
VitalBulkVitalShake30 mgper 44 Gram(s)DSLD:258778
Vitamer LaboratoriesHair, Skin & Nails Multi250 mgper 1 Tablet(s)DSLD:3214
Vitamin WorldHealthy Hair Formula1,000 mgper 3 Capsule(s)DSLD:64659
Vitamin WorldL-Cysteine 500 mgL-Cysteine Free Form500 mgper 1 Capsule(s)DSLD:20602
Vitamin WorldVitamins For The HairL-Cysteine Hydrochloride · L-Cystine (Form: as L-Cystine Hydrochloride)334 mgper 3 Caplet(s)DSLD:1197
Viva VitaminsHair400 mgper 1 Tablet(s)DSLD:250441
Viva VitaminsNails100 mgper 2 Tablet(s)DSLD:1786
ViviscalHair Self-Care15 mgper 1 Capsule(s)DSLD:317562
Wonder LaboratoriesEyeguardL-Cysteine Hydrochloride30 mgper 1 Capsule(s)DSLD:260556
Wonder LaboratoriesEyeguardL-Cysteine Hydrochloride30 mgper 1 Capsule(s)DSLD:262312
Wonder LaboratoriesEyeguardL-Cysteine Hydrochloride30 mgper 1 Capsule(s)DSLD:315178
Wonder LaboratoriesVision AllL-Cysteine Hydrochloride60 mgper 2 Capsule(s)DSLD:262384
Wonder LaboratoriesVision AllL-Cysteine Hydrochloride60 mgper 2 Capsule(s)DSLD:325891
XtendlifeImmu-Stay99 mgper 3 Capsule(s)DSLD:318033
XtendlifeTotal Balance Children's20 mgper 3 Tablet(s)DSLD:318023
XtendlifeTotal Balance Men's Premium50 mgper 7 Tablet(s)DSLD:331309
XtendlifeTotal Balance Unisex Premium50 mgper 6 Tablet(s)DSLD:283408
XtendlifeTotal Balance Women's Premium50 mgper 7 Tablet(s)DSLD:331312
XtendlifeViral-Protec99 mgper 3 Tablet(s)DSLD:17058
XYMOGENOptiCleanse Plus Rice Original463 mgper 53 Gram(s)DSLD:6563
XYMOGENOptiCleanse Plus Rice Raspberry Lemonade55 mgper 60 Gram(s)DSLD:6562
Zenith LabsHair revital x100 mgper 2 Capsule(s)DSLD:326182
Zenith LabsJoint n-11100 mgper 2 Capsule(s)DSLD:326183

Label record: NIH Office of Dietary Supplements · CC0

Registered, and not reported

Source: ClinicalTrials.gov
Intervention: L-cysteine
Status: Completed, terminated or suspended
Results posted: No

Trials without posted results

330 trials

330 registered trials without posted results · Overdue (FDAAA 801): 107 · Showing 120 of 330

107 past the window13 within it, or no actual date

Order

NCT05936528completed2026-07-05a university or hospital
NCT04828226completed2026-05-16a university or hospital
NCT07477275completed2026-04-30industry
NCT05610072completed2026-03-27a university or hospital
NCT04300920completed2026-03-02a university or hospital
NCT06298383completed2026-02-15a university or hospital
NCT04491526terminated— The study was terminated prematurely following a pre-planned interim analysis demonstrating futility2026-02-09a university or hospital
NCT07185386completed2026-01-22industry
NCT06650384completed2026-01-01a university or hospital
NCT07391163completed2026-01-01a university or hospital
NCT02583672completed2025-12-31a university or hospital
NCT07323719completed2025-12-01a university or hospital

Show the remaining 318

NCT06828120completed2025-09-03industrypast the reporting window
NCT05944458completed2025-06-01a university or hospitalpast the reporting window
NCT06252441completed2025-05-14a university or hospitalpast the reporting window
NCT05798481completed2025-04-29a university or hospitalpast the reporting window
NCT06039384terminated— This was a strategic business decision. There were no safety concerns contributing to this decision.2025-04-11industrypast the reporting window
NCT06377631completed2025-04-08a university or hospitalpast the reporting window
NCT05604586completed2025-03-15a university or hospitalpast the reporting window
NCT07082621completed2025-03-09a university or hospitalpast the reporting window
NCT05309070completed2025-02-28a university or hospitalpast the reporting window
NCT07059533completed2025-01-31a university or hospitalpast the reporting window
NCT06236165completed2025-01-22a university or hospitalpast the reporting window
NCT04793646completed2024-12-31a university or hospitalpast the reporting window
NCT03423667terminated— Difficulties in recruitment (single addictions become rare)2024-12-17a university or hospitalpast the reporting window
NCT06834711completed2024-12-12a university or hospitalpast the reporting window
NCT04154982completed2024-12-02a university or hospitalpast the reporting window
NCT06486805completed2024-11-30a university or hospitalpast the reporting window
NCT04140214completed2024-09-30a university or hospitalpast the reporting window
NCT05843669completed2024-09-30a university or hospitalpast the reporting window
NCT06482034completed2024-09-30a university or hospitalpast the reporting window
NCT07097727completed2024-09-30a university or hospitalpast the reporting window
NCT07184398completed2024-09-30a university or hospitalpast the reporting window
NCT04918719completed2024-09-17a university or hospitalpast the reporting window
NCT06115408completed2024-08-31a university or hospitalpast the reporting window
NCT03972592completed2024-08-14a university or hospitalpast the reporting window
NCT05598749completed2024-07-03industrypast the reporting window
NCT06105060completed2024-06-17a university or hospitalpast the reporting window
NCT06122311completed2024-06-10a university or hospitalpast the reporting window
NCT05485558completed2024-06-01a university or hospitalpast the reporting window
NCT05589584completed2024-05-20a university or hospitalpast the reporting window
NCT05804123completed2024-04-05industrypast the reporting window
NCT06139952completed2024-03-01a university or hospitalpast the reporting window
NCT05287724completed2024-01-04a university or hospitalpast the reporting window
NCT03956888completed2023-12-30a university or hospitalpast the reporting window
NCT05807204completed2023-12-20a university or hospitalpast the reporting window
NCT06252519completed2023-12-13a university or hospitalpast the reporting window
NCT07265102completed2023-12-05a university or hospitalpast the reporting window
NCT06141291completed2023-10-22a university or hospitalpast the reporting window
NCT05903014completed2023-09-30a university or hospitalpast the reporting window
NCT05757050completed2023-08-21industrypast the reporting window
NCT07080190completed2023-06-30a university or hospitalpast the reporting window
NCT03154580completed2023-06-27a university or hospitalpast the reporting window
NCT07398924completed2023-06-06a university or hospitalpast the reporting window
NCT05472285completed2023-05-23industrypast the reporting window
NCT05098249completed2023-05-09a university or hospitalpast the reporting window
NCT04226456terminated— poor recruitment2023-05-03a university or hospitalpast the reporting window
NCT05927259completed2023-05-01a university or hospitalpast the reporting window
NCT04920448terminated— lack of patients2023-04-25a university or hospitalpast the reporting window
NCT04703036terminated— Futility due to inability to recruit participants meeting entry criteria.2023-03-31a university or hospitalpast the reporting window
NCT06218225completed2023-03-31a university or hospitalpast the reporting window
NCT07470242completed2023-03-07a university or hospitalpast the reporting window
NCT02505477completed2023-01-31a university or hospitalpast the reporting window
NCT07340944completed2023-01-09a university or hospitalpast the reporting window
NCT07749287completed2023-01-01a university or hospitalpast the reporting window
NCT04595188completed2022-12-31a university or hospitalpast the reporting window
NCT05924061completed2022-12-31a university or hospitalpast the reporting window
NCT06804083completed2022-12-31a university or hospitalpast the reporting window
NCT04887194completed2022-12-22industrypast the reporting window
NCT05215743completed2022-11-22a university or hospitalpast the reporting window
NCT04939792completed2022-10-31a university or hospitalpast the reporting window
NCT04784234terminated— company was bought and discontinued producing supplement2022-10-27a university or hospitalpast the reporting window
NCT05951712completed2022-08-20a university or hospitalpast the reporting window
NCT02124941completed2022-08-14a university or hospitalpast the reporting window
NCT04458298terminated— Lack of enrollment2022-08-12industrypast the reporting window
NCT04015557suspended— Study was interrupted due to COVID-19 pandemicexpected 2022-06-30a university or hospital
NCT05523791completed2022-06-30a university or hospitalpast the reporting window
NCT03911076terminated— Slow recruitment/funding2022-06-08a university or hospitalpast the reporting window
NCT04923555completed2022-06-07a university or hospitalpast the reporting window
NCT04916080completed2022-06-01a university or hospitalpast the reporting window
NCT04554888completed2022-05-31a university or hospitalpast the reporting window
NCT04897698completed2022-05-09a university or hospitalpast the reporting window
NCT03711838completed2022-05-01a university or hospitalpast the reporting window
NCT04701346completed2022-03-17a university or hospitalpast the reporting window
NCT04519073completed2022-03-02industrypast the reporting window
NCT03702738completed2021-12-31a university or hospitalpast the reporting window
NCT07093944completed2021-12-22a university or hospitalpast the reporting window
NCT03596125terminated— difficulty of recruitment2021-11-11a university or hospitalpast the reporting window
NCT04449536completed2021-10-21a university or hospitalpast the reporting window
NCT04792021completed2021-09-13a university or hospitalpast the reporting window
NCT05264584completed2021-09-01a university or hospitalpast the reporting window
NCT05658549completed2021-07-30a university or hospitalpast the reporting window
NCT05387330completed2021-07-25a university or hospitalpast the reporting window
NCT07360704completed2021-07-01a university or hospitalpast the reporting window
NCT04711044completed2021-06-30a university or hospitalpast the reporting window
NCT05911282completed2021-06-30a university or hospitalpast the reporting window
NCT04515056completed2021-06-01a university or hospitalpast the reporting window
NCT04557410completed2021-05-25a university or hospitalpast the reporting window
NCT04657874completed2021-05-15a university or hospitalpast the reporting window
NCT04419025completed2021-05-14a university or hospitalpast the reporting window
NCT05242718completed2021-05-01industrypast the reporting window
NCT03730064completed2021-03-01a university or hospitalpast the reporting window
NCT05840640completed2021-02-28a university or hospitalpast the reporting window
NCT03636932completed2021-02-04a university or hospitalpast the reporting window
NCT03149107terminated— Recruitment not sufficient2021-01a university or hospitalpast the reporting window
NCT03510741completed2020-12-30a university or hospitalpast the reporting window
NCT04900129completed2020-12-30a university or hospitalpast the reporting window
NCT05611086terminated— The study stopped because the study period already ended2020-12-03a university or hospitalpast the reporting window
NCT04570254completed2020-12-01a university or hospitalpast the reporting window
NCT04023266completed2020-11-15a university or hospitalpast the reporting window
NCT04209803completed2020-09-02a university or hospitalpast the reporting window
NCT02094625completed2020-09a university or hospitalpast the reporting window
NCT02994875completed2020-09a university or hospitalpast the reporting window
NCT04405193completed2020-07-30a university or hospitalpast the reporting window
NCT04006301completed2020-07-13industrypast the reporting window
NCT05100680completed2020-05-30a university or hospitalpast the reporting window
NCT04170439completed2020-05-02a university or hospitalpast the reporting window
NCT03056014terminated— COVID2020-03-12a university or hospitalpast the reporting window
NCT03494387completed2020-03-01a university or hospitalpast the reporting window
NCT04009889completed2020-02-20industrypast the reporting window

Where it reaches

10 systems, 25 regions, 123 tissues, 249 transporter routes — routes, not measurements: transporters known to carry L-cysteine are expressed there, and no source reports it arriving.

Loading the model…

Nervous

Endocrine

Respiratory

Cardiovascular

Digestive

Urinary

Reproductive

Blood and immune

Musculoskeletal

Skin and adipose

Papers screened

1,354 papers

Compound: L-cysteine
Screened: 1,354
Admitted: 2
Discarded: 1,028
Not read: 324
Showing: 200 of 1,354

The whole record

Produced a finding2 papers

PMID:251399792026-10-11

and 1 more.

Read and discarded1,028 papers

PMID:20207721no claim extracted — subject_is_the_outcome — DOSED: acetaminophen 15 mg/kg and diets with 0% or 100% RDA of sulfur amino acids (methionine plus cysteine), abstract2026-10-11
PMID:24145571no claim extracted — no_outcome_node — measured: corneal epithelial re-epithelialization time after PRK, daily slit-lamp evaluation, mean days to complete healing | corneal epithelial re-epithelialization time after PRK, daily slit-lamp biomicroscopy, mean days to complete healing2026-10-11
PMID:24598154no claim extracted — subject_is_the_outcome — DOSED: methionine supplement 0.5 mmol/kg/d, versus alanine control (abstract only) | methionine versus alanine (control), 0.5 mmol/kg/d, abstract only2026-10-11
PMID:32160926no claim extracted — cause not determined2026-10-11
PMID:33531059no claim extracted — combination_exposure2026-10-11
PMID:39333704no claim extracted — subject_absent — DOSED: HITHION YH-15 Torula yeast extract, 325 mg/3 tablets/day containing 48 mg cysteine peptides (GSH, GSSG, gamma-Glu-Cys, Cys-Gly), Methods | HITHION YH-15 Torula yeast extract, 325 mg/3 tablets/day, standardised to 48 mg/day of 'cysteine peptides' (reduced and oxidized glutathione, gamma-glutamylcysteine, cysteinylglycine), Methods Intervention2026-10-11
PMID:41482382no claim extracted — quote_not_self_supporting2026-10-11
PMID:42143315no claim extracted — subject_absent — DOSED: cysteine dioxygenase type 1 (CDO1) gene expression and methylation as a prognostic biomarker; no cysteine administered | No compound given; the paper is about expression of the enzyme gene CDO1 as a prognostic biomarker in colorectal cancer (TCGA, GEO, abstract only)2026-10-11
PMID:42163118no claim extracted — combination_exposure2026-10-11
PMID:42588049no claim extracted — combination_exposure2026-10-11
PMID:42626963no claim extracted — subject_is_the_outcome2026-10-11
PMID:10349300L-cysteine: excluded by "ethylcysteine" in the title2026-10-05

and 1,016 more.

Not read yet324 papers

PMID:104696082026-10-13
PMID:166207952026-10-13
PMID:182539342026-10-09
PMID:162237322026-10-09
PMID:110770472026-10-07
PMID:88641132026-10-07
PMID:146959382026-10-06
PMID:63737702026-10-05

and 316 more.

Measured, not recorded

Compound: L-cysteine
Endpoints measured: 453 endpoints
Recorded as a finding: No

Show what was measured

Composite: death by 36 weeks PMA, BPD, death-or-BPD, ROP, severe ROP, NEC requiring surgery, periventricular leukomalacia, IVH, severe IVH (NAC arm)
no effect
N-acetylcysteine supplementation did not significantly affect the risks of death by 36 postmenstrual weeks, bronchopulmonary dysplasia (BPD), death or BPD, retinopathy of prematurity (ROP), severe ROP, necrotizing enterocolitis requiring surgery, periventricular leukomalacia, intraventricular hemorrhage (IVH), or severe IVH.
PMID:17054219 · one of two readings recorded this
Neonatal growth (unspecified anthropometric outcome), cysteine or N-acetylcysteine supplementation
no effect
Not recorded as a finding: No matching outcome node; the paper never names a specific anthropometric instrument (weight gain velocity, length, head circumference) for 'growth'
Growth was not significantly affected by cysteine supplementation (evaluated in one quasi-randomized trial) or by N-acetylcysteine supplementation (evaluated in one RCT).
PMID:17054219 · one of two readings recorded this
Neonatal growth
no effect
Growth was not significantly affected by cysteine supplementation (evaluated in one quasi-randomized trial) or by N-acetylcysteine supplementation (evaluated in one RCT).
PMID:17054219 · one of two readings recorded this
Nitrogen retention (mg/kg/day), cysteine supplementation of cysteine-free parenteral nutrition
increases, WMD 31.8 mg/kg/day (95% CI +8.2, +55.4), n = 95
Not recorded as a finding: No CAT:outcome node for nitrogen retention/balance exists in the outcome list
Nitrogen retention was significantly increased by cysteine supplementation (studied in four trials) (WMD 31.8 mg/kg/day, 95% confidence interval +8.2, +55.4, n = 95, including 73 preterm infants).
PMID:17054219 · one of two readings recorded this
Nitrogen retention (mg/kg/day)
increases, WMD 31.8 mg/kg/day (95% CI +8.2, +55.4), n = 95
Nitrogen retention was significantly increased by cysteine supplementation (studied in four trials) (WMD 31.8 mg/kg/day, 95% confidence interval +8.2, +55.4, n = 95, including 73 preterm infants).
PMID:17054219 · one of two readings recorded this
Plasma cysteine levels
increases
Plasma levels of cysteine were significantly increased by cysteine supplementation but not by N-acetylcysteine supplementation.
PMID:17054219 · one of two readings recorded this
plasma cysteine/cystine redox potential (EhCySS)
increases
With SAA intake at 100% RDA, APAP administration oxidized the plasma cysteine/cystine redox potential (E(h)CySS) but not the plasma GSH/GSSG redox potential (E(h)GSSG)
PMID:20207721 · one of two readings recorded this
plasma EhCySS oxidation by 0% SAA without APAP
increases
The extent of oxidation caused by APAP was similar to that seen with 0% SAA and no APAP
PMID:20207721 · one of two readings recorded this
plasma EhCySS with APAP plus 0% SAA versus either alone
no effect
However, APAP administration with 0% SAA did not cause further oxidation beyond APAP or 0% SAA alone
PMID:20207721 · one of two readings recorded this
plasma GSH/GSSG redox potential (EhGSSG) with SAA insufficiency
increases
In contrast, an oxidation of the plasma E(h)GSSG was apparent for SAA insufficiency only with APAP
PMID:20207721 · one of two readings recorded this
plasma GSH/GSSG redox potential (EhGSSG)
no effect
With SAA intake at 100% RDA, APAP administration oxidized the plasma cysteine/cystine redox potential (E(h)CySS) but not the plasma GSH/GSSG redox potential (E(h)GSSG)
PMID:20207721 · one of two readings recorded this
all-cause mortality
no effect
Nor could any statistically significant difference in all-cause mortality be demonstrated (RR 0.75; 95% CI 0.17 to 3.36)
PMID:20393967 · one of two readings recorded this
incidence of kwashiorkor
no effect
No statistically significant difference in the incidence of kwashiorkor between the intervention and control groups could be demonstrated at 20 weeks (RR 1.70; 95% CI 0.98 to 2.42)
PMID:20393967 · one of two readings recorded this
best corrected visual acuity (BCVA) after PRK
no effect
No statistically significant differences were observed regarding haze prevalence or BCVA after PRK between Group 1 and Group 2
PMID:24145571 · one of two readings recorded this
complete re-epithelialization in all patients
we observed complete re-epithelialization in all patients treated with topical b-FGF eye drops plus oral L-cysteine supplementation at Day 5
PMID:24145571 · one of two readings recorded this
complete re-epithelialization in all patients
the patients in Group 2, who were treated with topical b-FGF only, did not achieve complete resurfacing until Day 6 or Day 7 after the surgical procedure
PMID:24145571 · one of two readings recorded this
corneal epithelial re-epithelialization time after photorefractive keratectomy, daily slit-lamp biomicroscopy, days to complete healing
decreases, 3.3 days vs 4.8 days
Not recorded as a finding: this platform holds no node for the endpoint
Moreover, subjects treated with b-FGF plus L-cysteine demonstrated a re-epithelialization time of 3.3 days ± SD 0.3, whereas patients treated with b-FGF only required a longer time to achieve a complete re-epithelialization (4.8 days ± SD 0.5).
PMID:24145571 · one of two readings recorded this
corneal epithelial re-epithelialization time after photorefractive keratectomy, daily slit-lamp evaluation, Kaplan-Meier
decreases, 3.3 days ± SD 0.3 with b-FGF plus L-cysteine versus 4.8 days ± SD 0.5 with b-FGF only
Not recorded as a finding: this platform holds no node for the endpoint
Moreover, subjects treated with b-FGF plus L-cysteine demonstrated a re-epithelialization time of 3.3 days ± SD 0.3, whereas patients treated with b-FGF only required a longer time to achieve a complete re-epithelialization (4.8 days ± SD 0.5).
PMID:24145571 · one of two readings recorded this
corneal haze prevalence
no effect
No statistically significant differences were observed regarding haze prevalence or BCVA after PRK between Group 1 and Group 2
PMID:24145571 · one of two readings recorded this
corneal re-epithelialization time
decreases, n = 120
subjects treated with b-FGF plus L-cysteine demonstrated a re-epithelialization time of 3.3 days ± SD 0.3, whereas patients treated with b-FGF only required a longer time to achieve a complete re-epithelialization (4.8 days ± SD 0.5)
PMID:24145571 · one of two readings recorded this
corneal re-epithelialization time
n = 120
subjects treated with b-FGF plus L-cysteine demonstrated a re-epithelialization time of 3.3 days ± SD 0.3, whereas patients treated with b-FGF only required a longer time to achieve a complete re-epithelialization (4.8 days ± SD 0.5)
PMID:24145571 · one of two readings recorded this
epithelial healing Kaplan-Meier comparison
increases, p = 0.0001
The Kaplan–Meier curves also demonstrated a statistically significant difference between the two groups (P < 0.0001) from Day 3 to Day 5 postsurgery
PMID:24145571 · one of two readings recorded this
eyes with complete epithelial resurfacing
Complete corneal epithelial resurfacing was achieved starting at Day 3 after PRK in 57% of the eyes included in the study group (Group 1) and in 44% of the eyes in the control group (Group 2)
PMID:24145571 · one of two readings recorded this
eyes with complete epithelial resurfacing
Complete corneal epithelial resurfacing was achieved starting at Day 3 after PRK in 57% of the eyes included in the study group (Group 1) and in 44% of the eyes in the control group (Group 2)
PMID:24145571 · one of two readings recorded this
eyes with complete healing at Day four
At Day four, 99% of the eyes included in Group 1 showed complete healing, while just 89% of the eyes in Group 2 achieved the same result
PMID:24145571 · one of two readings recorded this
eyes with complete healing at Day four
At Day four, 99% of the eyes included in Group 1 showed complete healing, while just 89% of the eyes in Group 2 achieved the same result
PMID:24145571 · one of two readings recorded this
change in plasma cysteine concentration, CP1 to CP2
increases, p = 0.05
In the methionine compared with the alanine group, cysteine flux derived from protein breakdown was faster at CP2 than CP1 (P < 0.05), and the change in plasma cysteine concentration from CP1 to CP2 was greater (P < 0.05)
PMID:24598154 · one of two readings recorded this
cysteine de novo synthesis
no effect
However, there was no evidence of a difference in cysteine de novo synthesis and its total flux or erythrocyte glutathione synthesis rate and concentration between groups
PMID:24598154 · one of two readings recorded this
cysteine flux derived from protein breakdown, CP2 vs CP1
increases, p = 0.05
In the methionine compared with the alanine group, cysteine flux derived from protein breakdown was faster at CP2 than CP1 (P < 0.05), and the change in plasma cysteine concentration from CP1 to CP2 was greater (P < 0.05)
PMID:24598154 · one of two readings recorded this
cysteine total flux
no effect
However, there was no evidence of a difference in cysteine de novo synthesis and its total flux or erythrocyte glutathione synthesis rate and concentration between groups
PMID:24598154 · one of two readings recorded this
erythrocyte glutathione concentration
no effect
However, there was no evidence of a difference in cysteine de novo synthesis and its total flux or erythrocyte glutathione synthesis rate and concentration between groups
PMID:24598154 · one of two readings recorded this
erythrocyte glutathione synthesis rate
no effect
However, there was no evidence of a difference in cysteine de novo synthesis and its total flux or erythrocyte glutathione synthesis rate and concentration between groups
PMID:24598154 · one of two readings recorded this
Anion gap at baseline
no effect, p = 0.5, n = 38
the anion gap at baseline was comparable (8±2 vs. 9±3, p=0.5)
PMID:25139979 · one of two readings recorded this
Anion gap post supplement on infusion day
increases, p = 0.01, n = 38
the CYS group had a higher mean anion gap post supplement on infusion day (12±3 vs. 9±4, p=0.01)
PMID:25139979 · one of two readings recorded this
Change in erythrocyte GSH, effect of lower enrollment weight (adjusted for treatment)
decreases, p = 0.04, n = 38
After adjusting for treatment assignment with a multivariate analysis, lower enrollment weight and the need for a RBC transfusion decreased the change in GSH (p=0.04 and 0.03), and RBC transfusion decreased the change in total glutathione (p=0.03)
PMID:25139979 · one of two readings recorded this
Change in erythrocyte GSH, effect of RBC transfusion (adjusted for treatment)
decreases, p = 0.03, n = 38
After adjusting for treatment assignment with a multivariate analysis, lower enrollment weight and the need for a RBC transfusion decreased the change in GSH (p=0.04 and 0.03), and RBC transfusion decreased the change in total glutathione (p=0.03)
PMID:25139979 · one of two readings recorded this
Change in erythrocyte GSH:GSSG ratio (infusion day minus baseline)
no effect, p = 0.3, n = 38
−1±2 vs. −4±3 vs mmol/L, p=0.3
PMID:25139979 · one of two readings recorded this
Change in erythrocyte reduced glutathione (GSH) (infusion day minus baseline)
increases, p = 0.02, n = 38
0.5±0.2 vs. −0.2±0.2, and 0.4±0.2 vs. −0.2±0.2 mmol/L, p=0.02 each
PMID:25139979 · one of two readings recorded this
change in erythrocyte total glutathione and GSH from baseline to infusion day (individual change)
increases, 0.5±0.2 vs −0.2±0.2 total glutathione and 0.4±0.2 vs −0.2±0.2 mmol/L GSH, p = 0.02
Not recorded as a finding: Change-from-baseline score; the reduced-glutathione node is a concentration. The one significant result of the trial.
However, the mean individual change (±SEM) in total glutathione and GSH (infusion day – baseline) in the CYS group was significantly higher and positive when compared to the ISO group, which was lower and negative (0.5±0.2 vs. −0.2±0.2, and 0.4±0.2 vs. −0.2±0.2 mmol/L, p=0.02 each).
PMID:25139979 · one of two readings recorded this
Change in erythrocyte total glutathione, effect of RBC transfusion (adjusted for treatment)
decreases, p = 0.03, n = 38
After adjusting for treatment assignment with a multivariate analysis, lower enrollment weight and the need for a RBC transfusion decreased the change in GSH (p=0.04 and 0.03), and RBC transfusion decreased the change in total glutathione (p=0.03)
PMID:25139979 · one of two readings recorded this
Change in erythrocyte total glutathione (infusion day minus baseline)
increases, p = 0.02, n = 38
0.5±0.2 vs. −0.2±0.2, and 0.4±0.2 vs. −0.2±0.2 mmol/L, p=0.02 each
PMID:25139979 · one of two readings recorded this
Chronic lung disease
no effect, p = 1, n = 38
Thirty eight percent of the CYS group and 35% of the ISO group developed chronic lung disease (p=1)
PMID:25139979 · one of two readings recorded this
Days requiring supplemental oxygen
no effect, p = 0.4, n = 38
Mean days requiring supplemental oxygen (44±46 vs. 38±46 days, p=0.4)
PMID:25139979 · one of two readings recorded this
Days requiring ventilation
no effect, p = 0.5, n = 38
ventilation (32±35 vs. 32±45 days, p=0.5)
PMID:25139979 · one of two readings recorded this
Erythrocyte GSH concentration at infusion day
no effect, n = 38
The CYS and ISO group means were not different for total glutathione, GSH, and GSH:GSSG, neither at enrollment nor infusion day (Table 2)
PMID:25139979 · one of two readings recorded this
Erythrocyte GSH:GSSG ratio at infusion day
no effect, n = 38
The CYS and ISO group means were not different for total glutathione, GSH, and GSH:GSSG, neither at enrollment nor infusion day (Table 2)
PMID:25139979 · one of two readings recorded this
Erythrocyte total glutathione concentration at infusion day
no effect, n = 38
The CYS and ISO group means were not different for total glutathione, GSH, and GSH:GSSG, neither at enrollment nor infusion day (Table 2)
PMID:25139979 · one of two readings recorded this
Fractional synthetic rate of glutathione (FSR-GSH)
no effect, p = 0.4, n = 38
The mean glutathione FSR-GSH (±SEM) was similar between the CYS group and ISO group (44±5 vs. 49±4 %/day, p=0.4)
PMID:25139979 · one of two readings recorded this
hospital length of stay, days
69±51 vs 67±65 days, p = 1
Not recorded as a finding: Sentence reports means and p=1 with no direction word, and the arm labels are used without a two-sided statement
The mean length of hospital stay was 69±51 and 67±65 days in the CYS group and ISO group, respectively (p=1).
PMID:25139979 · both readings recorded this
in-hospital death
5% vs 12%, p = 0.6
Not recorded as a finding: No direction word in the sentence; counts only
One subject (5%) in the CYS group and two subjects (12%) in the ISO group expired during the hospital stay (p=0.6).
PMID:25139979 · one of two readings recorded this
In-hospital death
no effect, p = 0.6, n = 38
One subject (5%) in the CYS group and two subjects (12%) in the ISO group expired during the hospital stay (p=0.6)
PMID:25139979 · one of two readings recorded this
Intracellular erythrocyte cysteine at infusion day
no effect, p = 0.3, n = 38
intracellular cysteine (91±86 vs. 75±78 µmol/L, p=0.3)
PMID:25139979 · one of two readings recorded this
Intracellular erythrocyte glutamate at infusion day
no effect, p = 0.8, n = 38
glutamate concentrations (454 ± 220 vs. 438 ± 189 µmol/L, p=0.8)
PMID:25139979 · one of two readings recorded this
Intracellular erythrocyte glycine at infusion day
no effect, p = 0.5, n = 38
glycine (386±311 vs. 389±275 µmol/L, p=0.5)
PMID:25139979 · one of two readings recorded this
Intraventricular hemorrhage grade III and IV
no effect, p = 1, n = 38
intraventricular hemorrhage grade III and IV (19% vs. 24%, p=1)
PMID:25139979 · one of two readings recorded this
late onset sepsis, culture-confirmed bloodstream infection after 72 hours of life
no effect, 38% vs 29%, p = 0.7
Not recorded as a finding: No outcome node matches sepsis incidence in neonates; infectious-complication-rate case definition is not stated to match
No difference was demonstrated in the incidence of late onset sepsis (38% vs. 29%, p=0.7).
PMID:25139979 · one of two readings recorded this
Late onset sepsis
no effect, p = 0.7, n = 38
late onset sepsis (38% vs. 29%, p=0.7)
PMID:25139979 · one of two readings recorded this
Length of hospital stay
no effect, p = 1, n = 38
The mean length of hospital stay was 69±51 and 67±65 days in the CYS group and ISO group, respectively (p=1)
PMID:25139979 · one of two readings recorded this
mean individual change in erythrocyte total glutathione and GSH, infusion day minus baseline, LC-MS/MS
increases, 0.5±0.2 vs. −0.2±0.2, and 0.4±0.2 vs. −0.2±0.2 mmol/L, p = 0.02
Not recorded as a finding: Node reduced-glutathione measures concentration; this is a change-from-baseline contrast, a secondary analysis and the paper's only significant result on glutathione
However, the mean individual change (±SEM) in total glutathione and GSH (infusion day – baseline) in the CYS group was significantly higher and positive when compared to the ISO group, which was lower and negative (0.5±0.2 vs. −0.2±0.2, and 0.4±0.2 vs. −0.2±0.2 mmol/L, p=0.02 each).
PMID:25139979 · one of two readings recorded this
Necrotizing enterocolitis
no effect, p = 1, n = 38
necrotizing enterocolitis (29% vs. 24%, p=1)
PMID:25139979 · one of two readings recorded this
PN study supplement days at infusion day
increases, p = 0.002, n = 38
PN study supplement days were higher in the CYS group when compared to the ISO group with a mean (±SD) of 9±0.7 vs. 7±3 days (p=0.002)
PMID:25139979 · one of two readings recorded this
Retinopathy of prematurity requiring laser treatment
no effect, p = 1, n = 38
need for laser treatment for retinopathy of prematurity (24% vs. 24%, p=1)
PMID:25139979 · one of two readings recorded this
Steady-state intracellular [13C2]glycine enrichment (MPE)
no effect, n = 38
was 5.7±0.5 (coefficient of variation: 13±2%) and 5.7±0.5 (coefficient of variation: 12±1%) for the CYS and ISO groups, respectively
PMID:25139979 · one of two readings recorded this
obsessive-compulsive disorder, trichotillomania and onychophagia symptom response across four randomized, double-blind, placebo-controlled studies
Not recorded as a finding: a review that discusses its trials without pooling them
Results remain inconclusive, but NAC may still be useful as a treatment for obsessive-compulsive spectrum disorders on an individual level, particularly as the compound has a relatively benign side-effect profile.
PMID:26629962 · one of two readings recorded this
obsessive-compulsive disorder, trichotillomania and onychophagia symptom severity
Results remain inconclusive, but NAC may still be useful as a treatment for obsessive-compulsive spectrum disorders on an individual level, particularly as the compound has a relatively benign side-effect profile.
PMID:26629962 · both readings recorded this
induction of cysteine resistance loci (ccdA, cefA) expression in response to cysteine
increases
we describe two novel cysteine-inducible systems that regulate the cysteine resistance of Pantoea ananatis
PMID:26883827 · one of two readings recorded this
acute renal dysfunction (risk difference)
no effect, p = 0.22
N-acetyl cysteine therapy did not reduce acute renal dysfunction in the high-risk cohort [RD -0.03 (-0.09 to 0.02); P = .22; I2 = 24%]
PMID:26913679 · one of two readings recorded this
early mortality
no effect, p = 0.63
Early mortality was 2.9% and 3.7% in the N-acetyl cysteine and control cohorts respectively; [RD 0 (-0.03 to 0.02); P = .63; I2 = 20%]
PMID:26913679 · one of two readings recorded this
hospital stay (length of stay)
no effect, p = 0.81
Hospital stay (mean length of stay 10.4 and 10.1 days in the N-acetyl cysteine and control cohorts, respectively) was also similar in both cohorts [WMD 0.17 (-0.02 to 0.37) days; P = .81]
PMID:26913679 · one of two readings recorded this
incidence of postoperative acute renal dysfunction
The incidence of postoperative acute renal dysfunction was 23% and 36% in the N-acetyl cysteine and control cohorts, respectively
PMID:26913679 · one of two readings recorded this
maximal change in creatinine levels after surgery
no effect, p = 0.39
Maximal change in creatinine levels after surgery was also comparable [standardized mean difference 0.07 (-0.23, 0.09); P = .39]
PMID:26913679 · one of two readings recorded this
amino acid changes involving arginine
Amino acid changes involving arginine were present in 44% of the patients, while those involving proline were present in 26%
PMID:28902129 · one of two readings recorded this
amino acid changes involving proline
Amino acid changes involving arginine were present in 44% of the patients, while those involving proline were present in 26%
PMID:28902129 · one of two readings recorded this
Asian ancestry among probands with a potentially pathogenic mutation
Of the ten probands that carried one of these four mutations, 80% were Asian, 60% had the p.R75P mutation
PMID:28902129 · one of two readings recorded this
cardiovascular risk factors
Of the 34 probands described in the 18 articles, 33% presented cardiovascular risk factors such as smoking, hypertension, and/or dyslipidemia
PMID:28902129 · one of two readings recorded this
dementia
and dementia (94%)
PMID:28902129 · one of two readings recorded this
family history of stroke and/or dementia
A family history of stroke and/or dementia was observed in 96% of the probands
PMID:28902129 · one of two readings recorded this
granular osmiophilic material deposits in skin biopsy
GOM deposits were found in six out of nine probands (67%)
PMID:28902129 · one of two readings recorded this
migraine
Clinical symptoms included migraine (93%)
PMID:28902129 · one of two readings recorded this
p.R75P mutation among probands with a potentially pathogenic mutation
Of the ten probands that carried one of these four mutations, 80% were Asian, 60% had the p.R75P mutation
PMID:28902129 · one of two readings recorded this
patients with complete NOTCH3 exon evaluation
A complete evaluation of the NOTCH3 exons was carried out in 29% (8 out of 28) of the patients
PMID:28902129 · one of two readings recorded this
probands without anterior temporal pole involvement
91% did not have anterior temporal pole involvement
PMID:28902129 · one of two readings recorded this
pseudobulbar palsy
pseudobulbar palsy (80%)
PMID:28902129 · one of two readings recorded this
psychiatric disturbances
psychiatric disturbances (100%)
PMID:28902129 · one of two readings recorded this
seizures
seizures (60%)
PMID:28902129 · one of two readings recorded this
stroke
stroke (100%)
PMID:28902129 · one of two readings recorded this
cholinesterase (ChE) activity in plasma and RBCs, by spectrophotometry
increases
Although cysteine-and not NAC-increased the ChE activity of both plasma and RBCs over those of dichlorvos, it did not increase them over those of a high dose of 2-PAM.
PMID:29062551 · one of two readings recorded this
Cholinesterase (ChE) activity of plasma and RBCs, by spectrophotometry
increases, n = 22
Although cysteine-and not NAC-increased the ChE activity of both plasma and RBCs over those of dichlorvos, it did not increase them over those of a high dose of 2-PAM.
PMID:29062551 · one of two readings recorded this
cardioprotective potential / oxidative stress and cardiac damage in diabetes-associated cardiovascular complications, across heterogeneous experimental studies
Not recorded as a finding: a review that discusses its trials without pooling them
A meta-analysis could not be performed because the included studies were heterogeneous and data from randomized clinical trials were unavailable.
PMID:29623672 · one of two readings recorded this
diabetes-associated cardiovascular/cardiac oxidative stress and damage
decreases
NAC exhibits strong potential for the protection of the diabetic heart at risk of myocardial infarction through inhibition of oxidative stress.
PMID:29623672 · one of two readings recorded this
inhibition and binding-site localization on the Asc1 transporter
Direct target interaction and binding site location between TM helices 6 and 10 were confirmed via site directed mutagenesis.
PMID:30821959 · one of two readings recorded this
Inhibition of asc1 transporter function and binding-site mapping, by mutagenesis and transport assay
Direct target interaction and binding site location between TM helices 6 and 10 were confirmed via site directed mutagenesis.
PMID:30821959 · one of two readings recorded this
adiposity-associated oxidative stress, inflammation, lipid accumulation and insulin sensitivity across pre-clinical obesity models
Overwhelming literature included in this review supports the ameliorative effects of NAC against such complications in both in vitro and in vivo models of obesity.
PMID:31254666 · one of two readings recorded this
Cysteine yield from glucose via a reconstituted in vitro biosynthetic pathway
10.5 mM cysteine produced from 20 mM glucose
Consequently, 10.5 mM cysteine could be produced from 20 mM glucose through the optimized pathway.
PMID:31396682 · one of two readings recorded this
cysteine yield from glucose via an in vitro assembled enzymatic pathway
10.5 mM cysteine produced from 20 mM glucose
Consequently, 10.5 mM cysteine could be produced from 20 mM glucose through the optimized pathway.
PMID:31396682 · one of two readings recorded this
In vitro cysteine yield from glucose via an 11-enzyme reconstituted thermophilic biosynthetic pathway
10.5 mM cysteine could be produced from 20 mM glucose through the optimized pathway
Not recorded as a finding: another reason, stated per paper
Consequently, 10.5 mM cysteine could be produced from 20 mM glucose through the optimized pathway.
PMID:31396682 · one of two readings recorded this
Disease-free survival by tumoral SPARC overexpression
no effect, HR 1.476 (95% CI 0.993-2.195), p = 0.054
As a result, SPARC overexpression in cancer cells was indicative of a higher risk of DFS, but the difference was not statistically significant (HR: 1.476; 95% CI: 0.993-2.195; p=0.054;.
PMID:31423511 · one of two readings recorded this
Overall survival by stromal SPARC overexpression
no effect, HR 1.261 (95% CI 0.908-1.751), p = 0.166, n = 3244
However, no significant relation was observed (HR: 1.261; 95% CI: 0.908-1.751; p=0.166;.
PMID:31423511 · one of two readings recorded this
Overall survival by tumoral SPARC overexpression
decreases, HR 1.478 (95% CI 1.143-1.910), p = 0.003, n = 4452
Despite the high heterogeneity among the studies (x =62.10, p<0.001, I =74.2%), the pooled HR with multivariate analysis was 1.478 (95% CI: 1.143-1.910; p=0.003;.
PMID:31423511 · one of two readings recorded this
Adipose tissue ACAC mRNA (log2-fold change)
unclear
ACAC (0.41 log2-fold change vs. Met/Cys-high, 95% CI − 0.12–0.94)
PMID:32160926 · one of two readings recorded this
Adipose tissue ACAC mRNA (log2-fold change)
increases
ACAC (0.63 log2-fold change vs. Met/Cys-high, 95% CI 0.19–1.07)
PMID:32160926 · one of two readings recorded this
Adipose tissue CPT1A mRNA (log2-fold change)
unclear
CPT1A (0.33: − 0.15–0.82)
PMID:32160926 · one of two readings recorded this
Adipose tissue DGAT1 mRNA (log2-fold change)
increases
in the Met/Cys-low group, with a 0.43 log2-fold change vs. Met/Cys-high after 7 days (95% CI 0.00–0.86)
PMID:32160926 · one of two readings recorded this
Adipose tissue DGAT1 mRNA (log2-fold change)
increases
DGAT1 (0.56, 0.14 –0.99)
PMID:32160926 · one of two readings recorded this
Adipose tissue FASN mRNA (log2-fold change)
unclear
FASN (0.58, − 0.11–1.28)
PMID:32160926 · one of two readings recorded this
Adipose tissue GCLC mRNA (log2-fold change)
unclear
GCLC (0.46, − 0.0–1.01)
PMID:32160926 · one of two readings recorded this
Adipose tissue GCLM mRNA (log2-fold change)
unclear
GCLM (0.37, − 0.17–0.91)
PMID:32160926 · one of two readings recorded this
Adipose tissue MTOR mRNA (log2-fold change)
unclear
MTOR (0.37, − 0.13–0.88)
PMID:32160926 · one of two readings recorded this
Adipose tissue MTOR mRNA (log2-fold change)
unclear
MTOR (0.49, − 0.01–0.99)
PMID:32160926 · one of two readings recorded this
Adipose tissue SCD1 mRNA (log2-fold change)
unclear
SCD1 (0.87, − 0.29–2.04)
PMID:32160926 · one of two readings recorded this
Adipose tissue SCD1 mRNA (log2-fold change)
unclear
SCD1 (1.13, − 0.02–2.29)
PMID:32160926 · one of two readings recorded this
Body weight (median)
n = 20
Median (range) body weight in kg were 83.2 (76, 108), 81.8 (73, 97) and 78.3 (68.4, 83.3) at baseline in the Met/Cys-low, Met/Cys-medium and Met/Cys-high groups, respectively
PMID:32160926 · one of two readings recorded this
Body weight (median)
no effect, n = 20
At the final visit, the median (range) body weight in kg were 83.2 (75.0, 106), 81.6 (72.0, 97.0) and 77.5 (68.2, 82.0)
PMID:32160926 · one of two readings recorded this
Change in ApoA1
no effect, p = 0.19
ApoA1 | 6.16 (− 3.33, 16.6) | 0.19 | − 4.05 (− 12.4, 5.04) | 0.35
PMID:32160926 · one of two readings recorded this
Change in ApoA1
no effect, p = 0.35
ApoA1 | 6.16 (− 3.33, 16.6) | 0.19 | − 4.05 (− 12.4, 5.04) | 0.35
PMID:32160926 · one of two readings recorded this
Change in ApoB/A1 ratio
no effect, p = 0.13
ApoB/A1 | − 13.3 (− 28.4, 4.88) | 0.13 | − 0.9 (− 17.7, 19.3) | 0.92
PMID:32160926 · one of two readings recorded this
Change in ApoB/A1 ratio
no effect, p = 0.92
ApoB/A1 | − 13.3 (− 28.4, 4.88) | 0.13 | − 0.9 (− 17.7, 19.3) | 0.92
PMID:32160926 · one of two readings recorded this
Change in ApoB
no effect, p = 0.39
ApoB | − 7.21 (− 22.4, 11) | 0.39 | − 3.08 (− 18.3, 15) | 0.70
PMID:32160926 · one of two readings recorded this
Change in ApoB
no effect, p = 0.7
ApoB | − 7.21 (− 22.4, 11) | 0.39 | − 3.08 (− 18.3, 15) | 0.70
PMID:32160926 · one of two readings recorded this
Change in body weight
no effect, p = 0.66
Body weight | − 0.29 (− 1.63, 1.08) | 0.66 | − 0.48 (1.70–0.75) | 0.42
PMID:32160926 · one of two readings recorded this
Change in body weight
no effect, p = 0.42
Body weight | − 0.29 (− 1.63, 1.08) | 0.66 | − 0.48 (1.70–0.75) | 0.42
PMID:32160926 · one of two readings recorded this
Change in C-peptide
no effect, p = 0.9
C-peptide | − 1.2 (− 19.5, 21.2) | 0.90 | − 4.19 (− 21.2, 16.5) | 0.65
PMID:32160926 · one of two readings recorded this
Change in C-peptide
no effect, p = 0.65
C-peptide | − 1.2 (− 19.5, 21.2) | 0.90 | − 4.19 (− 21.2, 16.5) | 0.65
PMID:32160926 · one of two readings recorded this
Change in glucose
no effect, p = 0.87
Glucose | 0.48 (− 5.3, 6.61) | 0.87 | − 0.73 (− 6.26, 5.13) | 0.79
PMID:32160926 · one of two readings recorded this
Change in glucose
no effect, p = 0.79
Glucose | 0.48 (− 5.3, 6.61) | 0.87 | − 0.73 (− 6.26, 5.13) | 0.79
PMID:32160926 · one of two readings recorded this
Change in HDL cholesterol
no effect, p = 0.5
HDL | 2.64 (− 5.26, 11.2) | 0.50 | − 0.68 (− 8.07, 7.3) | 0.85
PMID:32160926 · one of two readings recorded this
Change in HDL cholesterol
no effect, p = 0.85
HDL | 2.64 (− 5.26, 11.2) | 0.50 | − 0.68 (− 8.07, 7.3) | 0.85
PMID:32160926 · one of two readings recorded this
Change in HOMA-IR
no effect, p = 0.23
HOMA-IRb | − 21.3 (− 47.8, 18.7) | 0.23 | − 10.3 (− 38.7, 31.2) | 0.55
PMID:32160926 · one of two readings recorded this
Change in HOMA-IR
no effect, p = 0.55
HOMA-IRb | − 21.3 (− 47.8, 18.7) | 0.23 | − 10.3 (− 38.7, 31.2) | 0.55
PMID:32160926 · one of two readings recorded this
Change in insulin
no effect, p = 0.26
Insulin | − 19.4 (− 45.6, 19.6) | 0.26 | − 10.8 (− 38.1, 28.6) | 0.52
PMID:32160926 · one of two readings recorded this
Change in insulin
no effect, p = 0.52
Insulin | − 19.4 (− 45.6, 19.6) | 0.26 | − 10.8 (− 38.1, 28.6) | 0.52
PMID:32160926 · one of two readings recorded this
Change in LDL cholesterol
no effect, p = 0.54
LDL | − 5.25 (− 21.2, 14) | 0.54 | − 6.69 (− 21.6, 11.1) | 0.41
PMID:32160926 · one of two readings recorded this
Change in LDL cholesterol
no effect, p = 0.41
LDL | − 5.25 (− 21.2, 14) | 0.54 | − 6.69 (− 21.6, 11.1) | 0.41
PMID:32160926 · one of two readings recorded this
Change in plasma SCD16 index
no effect, p = 0.19
SCD16a | − 12 (− 27.8, 7.37) | 0.19 | − 15.7 (− 30.9, 2.84) | 0.087
PMID:32160926 · one of two readings recorded this
Change in plasma SCD16 index
no effect, p = 0.087
SCD16a | − 12 (− 27.8, 7.37) | 0.19 | − 15.7 (− 30.9, 2.84) | 0.087
PMID:32160926 · one of two readings recorded this
Change in plasma SCD18 index
no effect, p = 0.22
SCD18a | 7.16 (− 4.46, 20.2) | 0.22 | 5.98 (− 5.02, 18.3) | 0.28
PMID:32160926 · one of two readings recorded this
Change in plasma SCD18 index
no effect, p = 0.28
SCD18a | 7.16 (− 4.46, 20.2) | 0.22 | 5.98 (− 5.02, 18.3) | 0.28
PMID:32160926 · one of two readings recorded this
Change in total cholesterol
no effect, p = 0.78
Total cholesterol | − 1.7 (− 13.2, 11.4) | 0.78 | − 4.62 (− 14.8, 6.8) | 0.39
PMID:32160926 · one of two readings recorded this
Change in total cholesterol
no effect, p = 0.39
Total cholesterol | − 1.7 (− 13.2, 11.4) | 0.78 | − 4.62 (− 14.8, 6.8) | 0.39
PMID:32160926 · one of two readings recorded this
Change in triglycerides
no effect, p = 0.63
Triglycerides | 8.51 (− 24, 55) | 0.63 | − 4.54 (− 31.7, 33.4) | 0.77
PMID:32160926 · one of two readings recorded this
Change in triglycerides
no effect, p = 0.77
Triglycerides | 8.51 (− 24, 55) | 0.63 | − 4.54 (− 31.7, 33.4) | 0.77
PMID:32160926 · one of two readings recorded this
Correlation of change in free reduced cysteine with change in adipose PRDM16 mRNA
increases
between free reduced cysteine and PRDM16 (r =0.61, 0.21–0.83)
PMID:32160926 · one of two readings recorded this
Correlation of change in protein-bound cysteine with change in adipose DGAT1 mRNA
increases
tCys and protein-bound cysteine with DGAT1 (r = 0.64, 95% CI 0.25–0.85; r = 0.57, 0.16–0.82, respectively)
PMID:32160926 · one of two readings recorded this
Correlation of change in protein-bound cysteine with change in adipose GCLM mRNA
increases
GCLM, with tCys (r = 0.57, 0.16–0.82), protein-bound cysteine (r = 0.59, 0.18–0.82), and taurine (r = 0.56, 0.15–0.81)
PMID:32160926 · one of two readings recorded this
Correlation of change in taurine with change in adipose GCLM mRNA
increases
GCLM, with tCys (r = 0.57, 0.16–0.82), protein-bound cysteine (r = 0.59, 0.18–0.82), and taurine (r = 0.56, 0.15–0.81)
PMID:32160926 · one of two readings recorded this
Correlation of change in total cysteine with change in adipose DGAT1 mRNA
increases
tCys and protein-bound cysteine with DGAT1 (r = 0.64, 95% CI 0.25–0.85; r = 0.57, 0.16–0.82, respectively)
PMID:32160926 · one of two readings recorded this
Correlation of change in total cysteine with change in adipose GCLM mRNA
increases
GCLM, with tCys (r = 0.57, 0.16–0.82), protein-bound cysteine (r = 0.59, 0.18–0.82), and taurine (r = 0.56, 0.15–0.81)
PMID:32160926 · one of two readings recorded this
Correlation of change in total cysteine with change in adipose SREBP mRNA
increases
between tCys and SREBP (r = 0.51, 0.073–0.78)
PMID:32160926 · one of two readings recorded this
Correlation of plasma total cysteine with BMI at baseline
unclear
Plasma total cysteine tended to correlate with BMI at baseline (r = 0.43, 95% CI − 0.02, 0.73)
PMID:32160926 · one of two readings recorded this
Ease of following the diets
n = 19
the participants reported that the diets were moderately easy to follow (39 points)
PMID:32160926 · one of two readings recorded this
Plasma free oxidized cystine response (group x time)
decreases, n = 13
Of the total cysteine fractions, there was a slight decrease in free oxidized cystine in the Met/Cys-low compared to the Met/Cys-high group
PMID:32160926 · one of two readings recorded this
Plasma methionine response (group x time)
decreases, n = 13
There was an overall decrease in methionine from baseline to day 7 in the Met/Cys-low group compared with the Met/Cys-high group
PMID:32160926 · one of two readings recorded this
Plasma SCD-16 index change
unclear
(− 15.4%, − 30.4–3.0%)
PMID:32160926 · one of two readings recorded this
Satisfaction with the diets
n = 19
Satisfaction with the diets was moderate (51 points on a 100-point scale)
PMID:32160926 · one of two readings recorded this
Self-reported diet compliance
no effect, n = 19
Self-reported compliance with the diets was ~ 95% among the participants
PMID:32160926 · one of two readings recorded this
Serum FGF21 (unadjusted median)
decreases, n = 6
whereas the concentrations decreased in the Met/Cys-medium and Met/Cys-high groups by 30% [from 98 (67, 232) to 69 (40, 426)] and 64% [from 75 (5, 291) to 27 (10, 332)], respectively
PMID:32160926 · one of two readings recorded this
Serum FGF21 (unadjusted median)
increases, n = 7
The unadjusted median serum FGF21 concentrations increased by 47% in the Met/Cys-low group from baseline to day 7 [median (range) from 96 pg/mL (38, 312) to 141 pg/mL (104, 432)]
PMID:32160926 · one of two readings recorded this
Serum FGF21 (unadjusted median)
decreases, n = 7
whereas the concentrations decreased in the Met/Cys-medium and Met/Cys-high groups by 30% [from 98 (67, 232) to 69 (40, 426)] and 64% [from 75 (5, 291) to 27 (10, 332)], respectively
PMID:32160926 · one of two readings recorded this
Urinary total cysteine
decreases, n = 19
Urinary concentrations of tCys were reduced in the Met/Cys-low and Met/Cys-medium groups compared to the Met/Cys-high group
PMID:32160926 · one of two readings recorded this
activation of cysteine-substituted AMPA/NMDA receptor currents by cadmium
increases
we generate AMPA and NMDA receptor subunits with homologous Cys substitutions and demonstrate similar activation of the mutant receptors by Cd.
PMID:32342094 · one of two readings recorded this
block of agonist-evoked current by Cd coapplication, WT GluN1/GluN2B
decreases
coapplication with 10 µM NMDA and glycine produced modest block (∼44.4%) of agonist-evoked current
PMID:32342094 · one of two readings recorded this
Cd half-maximal inhibition of steady-state potentiation, GluA1 L10C plus γ-2 TARP
decreases, p = 0.02
1.6 ± 0.3 mM for the decline in steady-state potentiation at higher Cd doses (P = 0.02, t test)
PMID:32342094 · one of two readings recorded this
Cd half-maximal potentiation of kainate-evoked current, GluA1 L10C plus γ-2 TARP
decreases, p = 0.0001
yielded significantly lower half-maximal values of 33 ± 6 µM for the rising phase of Cd potentiation (P < 0.0001, t test)
PMID:32342094 · one of two readings recorded this
Channel current activation of Cys-substituted iGluR mutants, by patch-clamp electrophysiology
increases
Here, we generate AMPA and NMDA receptor subunits with homologous Cys substitutions and demonstrate similar activation of the mutant receptors by Cd.
PMID:32342094 · one of two readings recorded this
holding current after MTSEA, GluA1 L10C
increases, p = 0.0001
displayed a significant increase in holding current following exposure to MTSEA (; P < 0.0001, two-way ANOVA)
PMID:32342094 · one of two readings recorded this
MTSEA reduction of activation, GluA1 L10C with versus without γ-2 TARP
increases, p = 0.021
MTSEA had a larger negative effect on activation of GluA1 L10C coexpressed with γ-2 TARP than on GluA1 L10C alone (; P = 0.021, two-way ANOVA)
PMID:32342094 · one of two readings recorded this
MTSEA reduction of Cd activation, GluA1 A8C with versus without γ-2 TARP
decreases, p = 0.0001
MTSEA was significantly less effective on GluA1 A8C coexpressed with γ-2 TARP (; P = 0.0001, two-way ANOVA)
PMID:32342094 · one of two readings recorded this
C-Nap1 phosphorylation in cells
decreases
cells treated with 23 displayed inhibition of C-Nap1 phosphorylation levels to approximately 20% of control at doses of 1 × GI50 (1.8 μM)
PMID:33479670 · one of two readings recorded this
Nek1 inhibition
decreases
23: IC50 = 20.8 μM; 24: 58% inhibition at 10 μM
PMID:33479670 · one of two readings recorded this
Nek2 inhibition by 6-vinylpurine 92
decreases
92 was found to be a very weak Nek2 inhibitor (17% inhibition at 10 μM)
PMID:33479670 · one of two readings recorded this
Nek2 kinase inhibition, IC50 by biochemical assay
IC50 0.06-0.15 µM (Nek2)
6-Ethynyl-N-phenyl-7H-purin-2-amine [IC50 0.15 μM (Nek2)] and 4-((6-ethynyl-7H-purin-2-yl)amino)benzenesulfonamide (IC50 0.14 μM) were selected for determination of the mode of inhibition of Nek2.
PMID:33479670 · one of two readings recorded this
recovery of Nek2 activity after rapid dilution
no effect
Compound 24 afforded only approximately 3% recovery of activity, compared with 11% for a control competitive inhibitor
PMID:33479670 · one of two readings recorded this
recovery of Nek2 activity after rapid dilution
unclear
Compound 24 afforded only approximately 3% recovery of activity, compared with 11% for a control competitive inhibitor
PMID:33479670 · one of two readings recorded this
Fasting glucose
n = 14
At baseline, median (range) fasting glucose concentrations were 5.0 (4.5, 5.2) and 4.8 (4.3, 6.0) mmol/L
PMID:33531059 · one of two readings recorded this
Fasting glucose
no effect, n = 14
After the 7-d intervention, fasting glucose concentrations were 5.0 (4.7, 5.2) and 4.8 (4.2, 5.8) mmol/L
PMID:33531059 · one of two readings recorded this
Glucose 2 h post-OGTT
n = 14
two hours post-OGTT concentrations were 4.4 (2.9, 5.1) and 4.9 (3.8, 6.7) mmol/L in the Met/Cyslow + PUFA and Met/Cyshigh + SFA groups, respectively
PMID:33531059 · one of two readings recorded this
Glucose 2 h post-OGTT
n = 14
2 h post-OGTT concentrations were 4.0 (3.7, 4.9) and 4.65 (3.9, 6) mmol/L in the Met/Cyslow + PUFA and Met/Cyshigh + SFA groups, respectively
PMID:33531059 · one of two readings recorded this
Plasma amino acids other than serine
no effect, n = 14
For the other amino acids, plasma concentrations responded similarly in both groups throughout the intervention with the exception of serine
PMID:33531059 · one of two readings recorded this
Plasma lactate
increases, n = 14
were similar for both groups with an initial increase to day 3 before approaching baseline values at day 7
PMID:33531059 · one of two readings recorded this
Plasma pyruvate
increases, n = 14
were similar for both groups with an initial increase to day 3 before approaching baseline values at day 7
PMID:33531059 · one of two readings recorded this
Plasma serine
n = 7
In the Met/Cyshigh + SFA group, plasma serine was 101 (59.8, 131) at baseline and 96.3 (65.5, 122) µmol/L at day 7
PMID:33531059 · one of two readings recorded this
Plasma serine
n = 7
Median (range) serine was 103 (76.4, 145) µmol/L in the Met/Cyslow + PUFA group at baseline and 123 (74.4, 141) µmol/L at day 7
PMID:33531059 · one of two readings recorded this
Serum total fatty acids
decreases, n = 14
The fatty acid response was generally similar in both groups with decreases in most fatty acids from baseline to day 7
PMID:33531059 · one of two readings recorded this
covalent crosslinking of kinases to ATP-MAc analogue
increases
Using in vitro kinase assays, ATP-MAc acts as a kinase co-substrate and covalently crosslinks only kinases containing cysteines in the active site.
PMID:33619842 · one of two readings recorded this
hepatic encephalopathy rate
decreases, 59% lower; OR, 0.41; CI, 0.20-0.83
Similarly, the rate of encephalopathy was 59% lower in the treatment group (OR, 0.41; CI, 0.20-0.83).
PMID:33722689 · one of two readings recorded this
mortality in non-acetaminophen induced acute liver injury, pooled odds ratio
decreases, OR, 0.47; CI, 0.29-0.75
Not recorded as a finding: this platform holds no node for the endpoint
Use of NAC in non-acetaminophen induced ALI showed 53% reduction in mortality compared to standard of care (OR, 0.47; CI, 0.29-0.75) and reduced mean duration of hospital stay by 6.52 days (95% CI, -12.91 to -0.13).
PMID:33722689 · one of two readings recorded this
mortality
decreases, 53% reduction; OR, 0.47; CI, 0.29-0.75
Use of NAC in non-acetaminophen induced ALI showed 53% reduction in mortality compared to standard of care (OR, 0.47; CI, 0.29-0.75) and reduced mean duration of hospital stay by 6.52 days (95% CI, -12.91 to -0.13).
PMID:33722689 · one of two readings recorded this
nausea and vomiting incidence
increases, OR, 3.99; CI, 1.42-11.19
However, the risk of developing nausea and vomiting (OR, 3.99; CI, 1.42-11.19), and the need for mechanical ventilation (OR 3.88; CI, 1.14-13.29) were significantly higher in the treatment group.
PMID:33722689 · one of two readings recorded this
need for mechanical ventilation
increases, OR 3.88; CI, 1.14-13.29
However, the risk of developing nausea and vomiting (OR, 3.99; CI, 1.42-11.19), and the need for mechanical ventilation (OR 3.88; CI, 1.14-13.29) were significantly higher in the treatment group.
PMID:33722689 · one of two readings recorded this
stomatal density and stomatal index
decreases
The stomatal density and stomatal index were decreased in crk33-2 and crk33-3 plants in comparison to wild-type plants, correlating with a decreased transpiration in transgenic plants and a higher drought tolerance.
PMID:33769202 · one of two readings recorded this
Ejaculate/sperm volume (mL), N-acetylcysteine vs placebo
increases, MD 0.69 mL (95% CI 0.26, 1.12), n = 431
Not recorded as a finding: No CAT:outcome node for ejaculate volume exists in the outcome list
Forest plots drew an MD of 0.69 ml and 95% CI [0.26, 1.12] (p =.002), which indicated that NAC had a significantly greater increase in sperm volume compared with the placebo.
PMID:33906513 · one of two readings recorded this
Normal sperm morphology (%), LC/LAC vs placebo
increases, MD 4.89 (95% CI 1.40, 8.39), n = 139
Forest plots drew an MD of 4.89 and 95% CI [1.40, 8.39] (p =.006), which indicated that LC/LAC had a better effect in raising normal morphology compared with the placebo.
PMID:33906513 · one of two readings recorded this
Normal sperm morphology (%), N-acetylcysteine vs placebo
increases, MD 1.68 (95% CI 0.79, 2.58), n = 431
Not recorded as a finding: No CAT:outcome node for sperm morphology exists in the outcome list
Forest plots drew an MD of 1.68 and 95% CI [0.79, 2.58] (p =.0002), which indicated that NAC had a significantly greater increase in normal morphology for infertile men compared with the placebo.
PMID:33906513 · one of two readings recorded this
Normal sperm morphology (%), NAC vs placebo
increases, MD 1.68 (95% CI 0.79, 2.58), n = 431
Forest plots drew an MD of 1.68 and 95% CI [0.79, 2.58] (p =.0002), which indicated that NAC had a significantly greater increase in normal morphology for infertile men compared with the placebo.
PMID:33906513 · one of two readings recorded this
Sperm concentration, LC/LAC vs placebo
no effect, MD 11.17*10^6/mL (95% CI -7.85, 30.20), p = 0.25, n = 190
Forest plots drew an MD of 11.17 *10^6/mL and 95% CI [–7.85, 30.20] (p =.25), which indicated that LC/LAC did not have a better effect in raising sperm concentration compared with the placebo.
PMID:33906513 · one of two readings recorded this
Sperm concentration, NAC vs placebo
increases, MD 3.80*10^6/mL (95% CI 2.36, 5.24), n = 431
Forest plots drew an MD of 3.80 *10^6/mL and 95% CI [2.36, 5.24] (p <.00001), which indicated that NAC had a significantly greater increase in sperm concentration compared with the placebo.
PMID:33906513 · one of two readings recorded this
Sperm/ejaculate volume, LC/LAC vs placebo
no effect, MD 11.17 mL (95% CI -7.85, 30.20), p = 0.25, n = 86
Forest plots drew an MD of 11.17 mL and 95% CI [–7.85, 30.20] (p =.25), which indicated that LC/LAC did not have a better effect in raising sperm volume compared with the placebo.
PMID:33906513 · one of two readings recorded this
Sperm/ejaculate volume, NAC vs placebo
increases, MD 0.69 mL (95% CI 0.26, 1.12), n = 431
Forest plots drew an MD of 0.69 ml and 95% CI [0.26, 1.12] (p =.002), which indicated that NAC had a significantly greater increase in sperm volume compared with the placebo.
PMID:33906513 · one of two readings recorded this
Sperm motility (%), LC/LAC vs placebo
increases, MD 9.48 (95% CI 0.95, 18.01), n = 190
Forest plots drew an MD of 9.48 and 95% CI [0.95, 18.01] (p = 0.03), which indicated that LC/LAC had a better effect in raising sperm motility compared with the placebo.
PMID:33906513 · one of two readings recorded this
Sperm motility (%), N-acetylcysteine vs placebo
increases, MD 4.69 (95% CI 2.45, 6.94), n = 431
Not recorded as a finding: No CAT:outcome node for sperm motility exists in the outcome list
Forest plots drew an MD of 4.69 and 95% CI [2.45, 6.94] (p <.0001), which indicated that NAC had a significantly greater increase in sperm motility compared with the placebo.
PMID:33906513 · one of two readings recorded this

The whole record — 453 rows

Sources cited

2 papers

Subject: L-cysteine
Findings: 6
Papers: 2

Other names

10 names

Resolves to: L-cysteine

Also called: (2R)-2-amino-3-mercaptopropanoic acid(2R)-2-amino-3-sulfanylpropanoic acid(R)-2-amino-3-mercaptopropanoic acidCysCYSTEINEE 920E-920E920FREE CYSTEINEL-2-Amino-3-mercaptopropionic acid